跳到正文
EMA 官方医药监管信息·精选AI 评分62

EMA 发布兽药 VGVP 信号管理模块修订草案并公开征求意见

Draft guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal Management - Revision 1

AI 导读

EMA 于 2026 年 9 月 18 日启动 VGVP 信号管理模块修订草案(EMA/522332/2021 Rev.1)的公开征求意见,截止 12 月 18 日。草案由 CVMP 于 9 月 10 日通过发布征求意见,内容覆盖信号检测、优先级排序、验证、评估、结果及风险最小化措施。该模块适用于欧盟各类审批程序授权的兽药及已登记的顺势疗法兽药,供上市许可持有人与主管当局履行药物警戒义务时使用。

推荐理由

材料列出兽药信号管理模块修订草案从信号检测到风险最小化措施的框架及征求意见安排,便于读者定位需核对的章节。

正文 · 原文

PDF 文字版;图形和原始排版请参阅官方 PDF。

第 1 页

1   18 September 2026
2   EMA/522332/2021 Rev.1
3   Committee for Veterinary Medicinal Products (CVMP)




4   Guideline on veterinary good pharmacovigilance practices
5   (VGVP) Module: Signal Management
6   Draft



      Date coming into effect of first version                                                                  28 January 2022

      Draft Revision 1 agreed by PhVWP-V                                                                         14 August 2026

      Draft Revision 1 adopted by CVMP for release for consultation                                        10 September 2026

      Start of public consultation                                                                         18 September 2026

      End of consultation (deadline for comments)                                                           18 December 2026

7
8
9
      Comments should be provided using this template. The completed comments form should be sent to
      vet-guidelines@ema.europa.eu

10
      Keywords                    Veterinary pharmacovigilance; signal management; Regulation (EU)
                                  2019/6; Union pharmacovigilance database
11




     Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
     Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
     Send us a question Go to www.ema.europa.eu/contact     Telephone +31 (0)88 781 6000       An agency of the European Union

     © European Medicines Agency, 2026. Reproduction is authorised provided the source is acknowledged.

第 2 页

12   Guideline on veterinary good pharmacovigilance practices
13   (VGVP) Module: Signal Management
14   Table of contents
15   1. Introduction (background) ...................................................................... 6
16   1.1. Definitions ........................................................................................................... 7

17   2. Signal Management process .................................................................. 11
18   2.1. Signal detection ................................................................................................. 13
19   2.1.1. Signal triggers................................................................................................. 14
20   2.1.2. Methods for signal detection ............................................................................. 16
21   2.2. Signal prioritisation............................................................................................. 23
22   2.2.1. Factors to consider during prioritisation .............................................................. 23
23   2.2.2. Impact on future prioritisation during ‘routine monitoring’ .................................... 32
24   2.3. Signal validation ................................................................................................. 33
25   2.3.1. Methods for signal validation ............................................................................. 34
26   2.3.2. Outcome of signal validation ............................................................................. 40
27   2.3.3. Signal prioritisation after signal validation........................................................... 41
28   2.4. Signal Assessment.............................................................................................. 41
29   2.4.1. Broader search for data .................................................................................... 42
30   2.4.2. Assessment of case series ................................................................................ 46
31   2.4.3. Investigation of biological mechanism ................................................................ 56
32   2.4.4. Special types of signals .................................................................................... 58
33   2.4.5. Risk characterisation ........................................................................................ 60
34   2.4.6. Overall conclusion............................................................................................ 65
35   2.5. Outcomes .......................................................................................................... 66
36   2.5.1. Signal refuted ................................................................................................. 66
37   2.5.2. Signal under close monitoring ........................................................................... 67
38   2.5.3. Signal requiring risk minimisation measures ....................................................... 68
39   2.6. Risk minimisation measures................................................................................. 68
40   2.6.1. Amendment of the product information .............................................................. 68
41   2.6.2. Additional risk communication ........................................................................... 69
42   2.6.3. Batch recall, suspension, withdrawal or revocation of the marketing authorisation ... 70
43   2.6.4. Other risk minimisation measures ...................................................................... 70

44   3. Reporting to the EU network ................................................................. 72
45   3.1. Signal management reporting obligations .............................................................. 72
46   3.1.1. Annual statements ........................................................................................... 72
47   3.1.2. Signal submissions .......................................................................................... 74
48   3.1.3. Pharmacovigilance Alerts .................................................................................. 76
49   3.2. Other reporting obligations .................................................................................. 76
50   3.2.1. Reporting of sales data and calculation of dose factor........................................... 76
51   3.2.2. Notification on regulatory measures from non-EU regulatory agencies/Information
52   from other regulatory authorities worldwide ................................................................. 77




     Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
     Management
     EMA/522332/2021 Rev.1                                                                                               Page 2/79

第 3 页

53   4. Targeted signal management by the competent authorities and the
54   Agency ...................................................................................................... 78
55   5. Documentation requirements related to the Signal Management Process
56   .................................................................................................................. 78
57
58
59
60
61




     Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
     Management
     EMA/522332/2021 Rev.1                                                                                       Page 3/79

第 4 页

62   Tabulated list of abbreviations
63
64   Abbreviation          Term
65   ABON                  Categories of the causality classification system for veterinary pharmacovigilance
66   AE                    Adverse Event
67   AER(s)                Adverse Event Report(s)
68   ALP                   Alkaline phosphatase
69   ALT                   Alanine transaminase
70   AMR                   Antimicrobial Resistance
71   AR                    Assessment report
72   ATCvet code           Standardised alphanumerical identifier used to classify veterinary medicinal products
73                         according to the Anatomical Therapeutic Chemical classification system for
74                         veterinary medicinal products
75   BPG                   Best Practice Guide
76   CAP(s)                Centrally Authorised Product(s)
77   CI(s)                 Confidence Interval(s)
78   CIR                   Commission Implementing Regulation
79   CVMP                  Committee for Veterinary Medicinal Products
80   DaHPC(s)              Direct Animal Healthcare Professional Communication(s)
81   DCP                   Decentralised Procedure
82   DLP                   Data Lock Point
83   DWH                   Data Warehouse
84   EEA                   European Economic Area
85   EMA                   European Medicines Agency
86   EU                    European Union
87   EVV                   EudraVigilance Veterinary
88   GABA                  Gamma-Aminobutyric Acid
89   GI                    Gastrointestinal
90   HCP                   Healthcare Professional
91   HLT                   High Level Term (VeDDRA hierarchy)
92   IC025                 Information Component (lower bound of the 95% confidence interval)
93   IgE                   Immunoglobulin E
94   IRIS                  EMA’s online platform for submitting and managing regulatory and scientific
95                         procedures for medicines throughout their lifecycle
96   IT                    Information technology
97   LEE                   Lack of Expected Efficacy
98   LLT                   Low Level Term (VeDDRA hierarchy)
99   MAH(s)                Marketing Authorisation Holder(s)
100   MDR1 mutation         Multidrug Resistance Gene Mutation 1 (also known as ABCB1 gene mutation)
101   MIT(s)                Medically Important Term(s)
102   MRP                   Mutual Recognition Procedure
103   NAP                   National Authorisation Procedure
104   NCA                   National Competent Authority
105   NOS                   Not otherwise specified (suffix to VeDDRA LLTs)
106   NSAID                 Nonsteroidal Anti-Inflammatory Drug
107   PCR                   Polymerase Chain Reaction
108   PD                    Pharmacodynamics
109   PhV                   Pharmacovigilance
110   PhVWP-V               Pharmacovigilance Working Party – Veterinary
111   PI                    Product information
112   PK                    Pharmacokinetics
113   PL                    Package leaflet
114   PMSS                  Post-Marketing Surveillance Study
115   PRR                   Proportional Reporting Ratio
116   PT                    Preferred Term (VeDDRA hierarchy)
117   QPPV                  Qualified Person for Pharmacovigilance
118   ROR                   Reporting Odds Ratio
119   SDR(s)                Signal(s) of Disproportionate Reporting
120   SOC                   System Organ Class (VeDDRA hierarchy)
121   SPC                   Summary of Product Characteristics
122   SRP                   Subsequent Recognition Procedure
123   TSM                   Targeted signal management
124   TTO                   Time-to-Onset

      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                              Page 4/79

第 5 页

125   UPD                   Union Product Database
126   UPhV-Database         Union Pharmacovigilance Database
127   VeDDRA                Veterinary Dictionary for Drug Regulatory Activities
128   VICH                  International Cooperation on Harmonisation of Technical Requirements for
129                         Registration of Veterinary Medicinal Products
130   VGVP                  Veterinary Good Pharmacovigilance Practices
131   VMP                   Veterinary Medicinal Product
132   VSM                   Veterinary signal management
133   WHO–UMC               World Health Organization – Uppsala Monitoring Centre




      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                            Page 5/79

第 6 页

134   1. Introduction (background)
135   This module of the guideline on veterinary good pharmacovigilance practices (VGVP) brings together
136   general guidance for marketing authorisation holders (MAHs), national competent authorities and the
137   European Medicines Agency (the ‘Agency’) regarding signal management for veterinary medicinal
138   products (VMPs) authorised in the European Union (EU).

139   The objectives of this module are:

140       •    To provide general guidance on scientific and quality aspects of signal management for VMPs;

141       •    To describe the roles, responsibilities and procedural aspects of the EU signal management
142            process for VMPs.

143   This module is applicable to VMPs authorised in the EU irrespective of the authorisation procedure
144   (centralised or national procedure, including mutual recognition, decentralised and subsequent
145   recognition procedures) and registered homeopathic VMPs.

146   This guidance is applicable to both MAHs and competent authorities in the fulfilment of their
147   pharmacovigilance obligations and provides a regulatory framework against which pharmacovigilance
148   inspections are conducted, ensuring consistent implementation, oversight and verification of
149   compliance. This module should be read in conjunction with Regulation (EU) 2019/6 of the European
150   Parliament and of the Council of 11 December 2018 on veterinary medicinal products and Commission
151   Implementing Regulation (EU) 2021/1281, laying down rules for the application of Regulation (EU)
152   2019/6 of the European Parliament and of the Council as regards good pharmacovigilance practice and
153   on the format, content and summary of the pharmacovigilance system master file for veterinary
154   medicinal products (the Implementing Regulation).

155   The Veterinary Good Pharmacovigilance Practices (VGVP) Module on Signal Management has been
156   revised based on the collective experience gained from all stakeholders involved in the signal
157   management process. It aims to provide a structured and practical framework for the identification,
158   evaluation and management of safety signals related to VMPs. The use of artificial intelligence tools in
159   signal management will be covered in a separate guidance document.

160   This revision aligns with international standards and the Veterinary Union Pharmacovigilance Database
161   – Best Practice Guide (BPG) and supports a harmonised, transparent and scientifically sound approach
162   to signal management. It also integrates the legal framework established by Regulation (EU) 2019/6,
163   particularly Article 81(2), which outlines the obligation to take appropriate action when new
164   information affects the benefit-risk balance of a VMP.

165   A key concept in this module is the ‘effect on the benefit–risk balance’, defined as any new
166   information, data or scientific interpretation that may influence the established understanding of a
167   product’s safety or efficacy profile 1. When such information emerges, MAHs are required to evaluate its
168   potential impact on the benefit–risk balance and determine whether regulatory or other actions are
169   warranted.

170   This module outlines the key steps in signal management, from detection to decision-making and
171   provides guidance on how to document and communicate findings effectively. This revision reflects
172   current best practices and incorporates insights from real-world pharmacovigilance activities. It
173   supports a proactive, consistent and scientifically sound approach to signal management. The module




      1 See also: Guideline on the evaluation of the benefit-risk balance of veterinary medicinal products

      (EMA/CVMP/248499/2007 – Rev.1)

      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                                  Page 6/79

第 7 页

174   emphasises the importance of clinical judgement, qualitative data review and transparent decision-
175   making throughout the signal evaluation process.

176   The term ‘clinical signs’ is used in this document in line with general understanding/ common
177   terminology and in the context of this guideline also refers to symptoms reported in humans.

178   Examples are provided in grey boxes throughout the text to aid understanding. They are used only to
179   illustrate complex concepts and should never be considered an exhaustive list of possible scenarios.

180   1.1. Definitions

       1        ABON system                  A causality assessment system previously used in European
                                             veterinary pharmacovigilance to classify the likelihood of a causal
                                             association between a veterinary medicinal product and an adverse
                                             event.
       2        Adverse event                Adverse events are defined in Article 73(2) of Regulation (EU)
                                             2019/6. The term adverse event implies that it is suspected. ‘Adverse
                                             event’ may also be used in veterinary pharmacovigilance to describe
                                             events included in the product information.
       3        Amendment of the             A type of regulatory action to the authorised product information to
                product                      reflect updated knowledge, including additions, modifications or
                information                  removal of existing information as authorised by the competent
                                             authorities.
       4        Annual Statement             A submission made in IRIS at least annually. It is the practical
                                             solution for MAHs to comply with the requirement set out in
                                             Regulation (EU) 2019/6 Art. 81(2) to ‘record, at least annually, all
                                             results and outcomes of the signal management process, including a
                                             conclusion on the benefit-risk balance’.
       5        Case series                  A group of individual case reports related to the same or similar event
                                             and product, analysed collectively.
       6        Causal association           The likelihood that a veterinary medicinal product caused an adverse
                                             event or contributed significantly to the occurrence of it.
       7        Causality                    A structured evaluation of the likelihood that a veterinary medicinal
                assessment                   product caused or contributed to an adverse event.

       8        Close monitoring             Enhanced pharmacovigilance activities applied to a signal for which
                                             the available evidence remains insufficient to warrant implementation
                                             of risk minimisation measures at this point in time, but which is
                                             subject to continued assessment to determine the need for future
                                             action and where new information is expected within a reasonable
                                             time frame. Deliberate effort is made to seek additional information in
                                             order to reach a conclusion. Submission of updates to a signal under
                                             close monitoring is expected at least annually. See section 2.5.2.
       9        Concurrent                   Medicinal products that are administered or used at the same time or
                products                     in close temporal proximity and that may contribute to or influence
                                             the occurrence of an adverse event. See also co-reported product.

       10       Confounding                  A variable that may influence the observed association between a
                factor                       product and an adverse event.

       11       Co-reported                  Medicinal products that are reported in the same adverse event
                products                     report, regardless of their temporal relationship or suspected
                                             involvement. See also concurrent products.




      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                                   Page 7/79

第 8 页

12       Data lock point              The point in time up to which data is included in a signal assessment
                                       or the last date covered by an annual statement.


13       Dechallenge                  The withdrawal of a veterinary medicinal product, or in some cases a
                                       reduction in dose, following the occurrence of the adverse event of
                                       interest.
14       Disproportionality           A method used to identify whether an adverse event is reported more
          in adverse event             frequently for a specific product or substance than would be
          reporting                    expected, typically based on comparison with other products in a
                                       database. Many different methods are available to determine
                                       disproportionality in AE reporting.
15       Dose–response                When a higher dose or prolonged treatment leads to an increased
          relationship                 occurrence of the event, or to increased severity of the event.
16       Educational                  Targeted materials designed to inform and guide users or animal
          material                     healthcare professionals to reduce risks and ensure the safe and
                                       appropriate use of a veterinary medicinal product.
17       Follow-up                    A subsequent assessment of a signal under close monitoring, where
          assessment of a              newly available information is assessed in context of the cumulative
          signal                       data.
18       Inflated                     When a bias falsely increase disproportionality, inflating it above the
          disproportionality           true level of disproportionality.
19       Lack of expected             A situation in which a veterinary medicinal product does not achieve
          efficacy (LEE)               the intended therapeutic effect under the approved conditions of use,
                                       as reflected by treatment failure or insufficient clinical response.

20       Masking of                   When a bias falsely lowers disproportionality, masking the true level
          disproportionality           of disproportionality.
21       Medically                    The MIT list comprises VeDDRA PTs that correspond to medical
          Important Terms              conditions which are commonly involved in suspected adverse events
          (MIT)                        across different pharmacological or therapeutic classes, or which are
                                       considered medically important independently of any established
                                       causal association with a veterinary medicinal product, due to their
                                       seriousness or potential impact on animal health or welfare, public
                                       health, user safety or the environment.
22       Medically linked             VeDDRA terms that are conceptually or clinically linked to the same
          VeDDRA term                  adverse event or underlying condition, representing different
                                       manifestations, stages, complications or descriptors of a shared
                                       pathophysiological process.
23       New aspect of a              Information relating to a known adverse event, such as changes in
          known risk                   frequency, severity, outcome, affected population or conditions of
                                       occurrence, which is not described in the currently approved product
                                       information.
24       New risk                     An adverse event or risk associated with a veterinary medicinal
                                       product which is not described in the currently approved product
                                       information.
25       Non-validated                A signal for which the signal validation process could not verify that
          signal                       the available data was of sufficient quality and substance and/or
                                       justify further investigation of the possibility of a causal association
                                       between the product(s)/substance(s) and the suspected adverse
                                       event(s) or where the events are considered adequately described in
                                       the product information.




Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
Management
EMA/522332/2021 Rev.1                                                                                    Page 8/79

第 9 页

26       Pharmacovigilance            Any suspected unexpected serious risk which may require urgent
          Alert                        regulatory action and communication by the MAH, or the competent
                                       authorities as referred to in Article 129, Article 130 and Article 134 of
                                       Regulation (EU) 2019/6.
27       Rechallenge                  The reintroduction or dose increase of a veterinary medicinal product
                                       after a dechallenge to assess whether the adverse event reoccurs or
                                       worsens.
28       Refuted signal               A validated signal for which, following further assessment, a causal
                                       association is not supported by the available evidence at the time of
                                       assessment.
29       Regulatory action            An intervention or decision arising from signal assessment and the
                                       evaluation of the benefit–risk balance, intended to address identified
                                       or potential risks associated with a veterinary medicinal product and
                                       to ensure its safe and effective use. A regulatory action can be
                                       initiated by the MAH or the responsible competent authority.
30       Reporting                    An estimate of the frequency of an adverse event, based on number
          incidence                    of reports in relation to estimated exposure (in accordance with the
                                       guideline on calculation of dose factor).
31       Reporting odds               A quantitative measure used in pharmacovigilance to detect
          ratio (ROR)                  disproportionate reporting, comparing the odds of reporting a specific
                                       adverse event for a given product with the corresponding odds for all
                                       other products in the database.
32       Risk based                   An approach in which the methodology, extent and frequency of
          approach                     pharmacovigilance activities are determined based on factors such as
                                       product characteristics, time on the market, safety profile and
                                       identified and potential risks and the need for additional information.
33       Risk                         The process of describing the nature, severity, frequency and
          characterisation             conditions of occurrence of a risk based on the totality of available
                                       evidence.
34       Risk minimisation            Interventions intended to reduce the occurrence, severity or impact of
          measures                     adverse events associated with a veterinary medicinal product
                                       through risk communication or other actions.
35       Routine                      The ongoing and systematic surveillance of safety information for a
          pharmacovigilance            veterinary medicinal product as part of standard pharmacovigilance
          monitoring                   activities, aimed at detecting, evaluating and managing potential
                                       risks.
36       Severity                     The intensity of an adverse event, reflecting the degree of deviation
                                       from normal clinical status (e.g. mild, moderate or severe), without
                                       implying its medical significance or outcome.
37       Signal                       Information that arises from one or multiple sources, including
                                       observations and studies which suggests a potentially new causal
                                       association, or a new aspect of a known causal association between
                                       an intervention and an adverse event or a set of related adverse
                                       events, that is judged likely to justify further investigation of possible
                                       causality (Art. 1(c) of CIR (EU) 2021/1281).
                                       ‘New’ should be understood as compared to the currently approved
                                       product information.
38       Signal assessment            The process of evaluating a validated signal through a comprehensive
                                       and structured review of all available data in order to assess the
                                       likelihood of a causal association and to support decision-making on
                                       appropriate action, if necessary.
39       Signal detection             The process aimed at identifying new potential signals through
                                       monitoring of post-authorisation safety data to identify patterns which
                                       could suggest a new potential risk or a new aspect to a known risk.

Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
Management
EMA/522332/2021 Rev.1                                                                                    Page 9/79

第 10 页

       40       Signal of                    Signals of disproportionate reporting (SDRs) refer to statistical
                disproportionate             associations between veterinary medicinal products and suspected
                reporting (SDR)              adverse events. It is important to separate the concepts of
                                             ‘disproportionate reporting’ in general from the specific concept of an
                                             SDR. The difference is that the latter reaches a pre-defined ‘level of
                                             disproportionality’. The criteria used to define an SDR are often
                                             specific to the database used for signal detection and the method
                                             used to calculate disproportionality.
       41       Signal outcome               The final conclusion of signal assessment reflecting the outcome and
                                             the subsequent proposed actions or follow-up, if necessary.
       42       Signal                       A continuous process aiming to evaluate the potential impact of a
                prioritisation               signal in comparison to other signals in order to identify relevance,
                                             determine urgency and perform efficient signal management through
                                             a risk-based approach.
       43       Signal                       A validated signal for which signal assessment supports a likely causal
                requiring risk               association between the veterinary medicinal product and the adverse
                minimisation                 event. The signal is considered to warrant risk minimisation
                measures                     measures.
       44       Signal trigger               The source from which a potential signal originates, initiating further
                                             evaluation through the signal management process.
       45       Signal validation            An initial screening of the data that triggered the potential signal,
                                             with the aim of determining whether the signal is supported by
                                             information of sufficient quality and substance to justify further
                                             assessment. Therefore, signal validation is not intended to determine
                                             causality.
       46       Supportive case              A case report that, based on assessment of relevant clinical and
                                             temporal factors, provides evidence supporting a causal association
                                             between an adverse event and a veterinary medicinal product.

       47       Temporal                     When the reported event(s) occurred after the time of exposure to
                association                  the veterinary medicinal product(s).

       48       Time-to-onset                The time interval between exposure to a veterinary medicinal product
                (TTO)                        and the onset of an adverse event.

       49       Validated signal             A signal is considered validated when the signal validation process
                                             has verified that the data triggering the signal is of sufficient quality
                                             and substance to justify a need for further analysis and the event(s)
                                             of the signal are not already adequately described in the product
                                             information.
181




      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                                    Page 10/79

第 11 页

182   2. Signal Management process
183   A ‘signal’ is defined as information that arises from one or multiple sources, including observations and
184   studies which suggests a potentially new causal association, or a new aspect of a known causal
185   association between an intervention and an adverse event or a set of related adverse events, that is
186   judged likely to justify further investigation of possible causality 2.

187   The ‘signal management process’ is defined in Article 4(41) of Regulation (EU) 2019/6; in practice, this
188   is the collective term used to describe the steps of signal detection, signal prioritisation, signal
189   validation, signal assessment and recommendation for action (risk mitigation) as a whole and the
190   outcome should be documented 3. It is a structured process that should enable continuous monitoring
191   of the benefit-risk balance of a product 4 and therefore should be conducted with a sufficient frequency
192   to ensure timely identification, assessment and management of potential risks related to the use of
193   VMPs.

194   A risk-based approach shall be applied to determine the methodology, extent and frequency of the
195   signal management process 5. The frequency of monitoring should be proportionate to the identified
196   risk4. Use of a risk-based approach means that the following key factors should be taken into account:
197   type of product, length of time on the market, stability of the pharmacovigilance profile, identified and
198   potential risks and the need for additional information5. The rationale for the chosen approach shall be
199   documented3 (see also section 5).

200   Application of a risk-based approach is not only fundamental but also dynamic throughout the signal
201   management process. Rather than applying a fixed set of criteria, a risk-based approach involves
202   continuously evaluating the context and evolving nature of the signal. By integrating the above-
203   mentioned key factors, the process ensures that clinical relevance and potential impact on public
204   health guide prioritisation and decision-making. This flexible strategy allows for more efficient use of
205   resources, focusing efforts on signals that pose the greatest potential risk or require urgent attention.




      2 Article 1(c) of the Commission Implementing Regulation (CIR) EU 2021/1281
      3 Article 17(1) of CIR (EU) 2021/1281
      4 Article 77(4) of Regulation (EU) 2019/6
      5 Article 17(3) of CIR (EU) 2021/1281


      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                                  Page 11/79

第 12 页

206


207      Figure 1: Signal management process


208   Throughout all phases of signal management, clinical judgement plays a critical role. It is essential not
209   only in interpreting data but also in selecting what data may support a potential signal. The ability to
210   discern meaningful patterns and assess clinical relevance is key to ensuring that signals are neither
211   overlooked nor overestimated.

212   Signal Detection:

213   The detection phase aims to identify new potential signals. It focuses on identifying new or changed
214   risks through detection of abnormal patterns or monitoring of new information. Signal detection should
215   be objective and non-biased and based on previous knowledge of the product and the pharmacological
216   and biological characteristics of the active substance. It should ideally be based on a combination of
217   quantitative (e.g. disproportionality, number of cases, number of reacting animals) and qualitative
218   (e.g. review of case narratives, literature reviews) methods.

219   Signal Prioritisation:

220   Signal prioritisation is an integral part of the signal management process and may be performed
221   continuously throughout the entire process. Prioritisation aims to evaluate the potential impact of a
222   signal in comparison to other signals in order to identify the most relevant signals, determine their
223   urgency and perform efficient signal management through a risk-based approach.

224   Signal Validation:

225   Signal validation aims to determine if additional analysis of a potential signal is warranted. It focuses
226   on determining whether the potential signal is supported by data of sufficient quality and substance to
227   justify further assessment.

228   Signal Assessment:

229   Signal assessment aims to decide whether any action is necessary. Through a broader and deeper
230   analysis of all available data pertaining to the signal, focus is placed on understanding the causal
231   relationship between the potential risk and the VMP and further characterisation of the risk.


      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                             Page 12/79

第 13 页

232   Outcomes and Risk minimisation measures:

233   This stage focuses on determining how to manage the potential risk and deciding on the optimal course
234   of action. It involves analysing the potential risk in relation to the benefits of the product,
235   recommending appropriate risk minimisation measures, if necessary, as well as documenting the
236   outcome of the signal management process.

237




238

239      Figure 2: Flow diagram of signal management process


240   2.1. Signal detection

241   Signal detection is the process of monitoring post-authorisation safety data for information that could
242   suggest a new potential risk or a new aspect to a known risk. Potential risks may be related to animal
243   or public health or to protection of the environment 6. The detection phase is focused on the



      6 Article 4(41) of Regulation (EU) 2019/6


      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                             Page 13/79

第 14 页

244   observation of new potential risks or new aspects and/or change in reporting patterns. The detection
245   phase generally does not require deep analysis of data.

246   Irrespective of the frequency of monitoring according to the chosen risk-based approach for a product,
247   MAHs are obliged to conduct a signal detection analysis for each of their active substances or products
248   in the Union pharmacovigilance database (UPhV-database) at least once a year 7. In practical terms,
249   the reference to UPhV-database means the EudraVigilance Veterinary Data Warehouse (EVV-DWH) in
250   this context. This analysis should be performed within 2 months of the annual due date (see also
251   section 3.1.1.2).

252   Signals may be detected from any source, using a variety of methods. This section will summarise the
253   most important considerations relevant for signal detection.

254   2.1.1. Signal triggers

255   The source of a detected signal is also called ‘the signal trigger’. Signals can arise from any source,
256   including e.g. from case reports, clinical trials, scientific literature or public/social media. Potential
257   signals should not be dismissed or validated based solely on their source. Regardless of the original
258   source of a potential signal, other data sources may be investigated for relevant evidence during
259   further assessment (see also section 2.4). Depending on the source of a potential signal, different
260   methods may be used to determine whether it should be treated as a signal (see also section 2.1.2).

261   Signal triggers for any signal progressing on to the validation stage should be recorded in a traceable
262   manner.

263   Below are examples of the more common signal triggers. The list should not be considered exhaustive.

264   2.1.1.1. Adverse event reports:

265   The most common signal trigger is adverse event (AE) reports. AE reports are the basis of adverse
266   event databases such as the UPhV-database (EVV-DWH) or the MAHs’ own safety databases. Many
267   MAHs maintain their own pharmacovigilance databases, which may be used for signal detection in
268   addition to the UPhV-database (EVV-DWH). AE reports in databases may be spontaneous or solicited
269   (e.g. from clinical trials) and may concern one or more suspected adverse events, lack of expected
270   efficacy, medication errors or a combination of these. The threshold for when AE reports trigger a
271   signal may vary and different methods can be applied to detect signals in databases (see section
272   2.1.2.1).

273   2.1.1.2. Scientific literature:

274   Monitoring of scientific literature can be used to detect potential signals arising from e.g. clinical trials,
275   non-interventional studies, literature reviews or meta-reviews, published case studies or case series or
276   potential signals pertaining to the active substance or to a class of substances (e.g. NSAIDs, beta-
277   lactam antibiotics etc.). Some of these types of literature may also be found as case reports in adverse
278   event databases.

279   2.1.1.3. Public/Social Media:

280   Monitoring of public and social media is usually part of the collection and recording of adverse events
281   as AERs in the UPhV-database (see also VGVP module on collection and recording of suspected adverse



      7 Article 17(7) of CIR (EU) 2021/1281


      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                                 Page 14/79

第 15 页

282   events for VMPs 8). In such cases, information from these sources is included in the signal management
283   process as AERs.

284   However, there may be situations where the information detected is not suitable for creation of AERs
285   for submission into the UPhV-database but may still constitute a signal trigger (i.e. justify further
286   investigation). It may be relevant to progress a signal from such a source through the signal
287   management process, to either be able to ease public concern or to ensure proper risk mitigation
288   measures are in place. Swift and thorough management of signals from media sources may also
289   contribute to maintain trust from the public. However, such signals should, like all other signals, be
290   further supported by other evidence in order to progress through the different steps of the signal
291   management process.

292   2.1.1.4. Other sources

293   Potential signals may be triggered from other sources than the ones mentioned above. Such sources
294   include, but are not limited to:

295       •     Requests for signal submissions from the CVMP or a national competent authority in the EEA.

296       •     Alerts, communications or reports from other regulatory authorities (non-EEA).

297       •     Communication from manufacturers or distributors (potential impact on quality).

298       •     Veterinary toxicology centres or human poison control centres.

299       •     Academic poster presentations, conferences or collaborations.

300       •     Environmental monitoring (e.g. for antiparasitics with wildlife impact).

301       •     Slaughterhouses (residues).

302       •     Signals arising from other signals; when patterns or associations noted during assessment of
303             one signal leads to other signals. This occurs most often with signals that are new aspects of
304             known risks but may also occur in more complex situations for new risks (see example 1).
305             Similarly, signals of interactions between two drugs may also arise from noticing patterns of
306             co-reported drugs during assessment of broader signals.

307       •     Direct communication from the public (e.g. a veterinarian, pet owner or farmer) providing
308             information of a nature not suited for a regular case report (e.g. questions, observation of
309             unspecific trends, complaints, etc.).

310       •     Ongoing post-marketing clinical trials.


           Example

           1:    A signal of an event, e.g. seizure, is suspected to be more serious in a subpopulation of the
                 target animal species which also have impaired renal function. This is suspected due to a
                 pattern of co-reporting of the event with kidney-related VeDDRA terms. The signal
                 assessment should therefore include an assessment of both the overall drug-event-
                 combination (all reports of any type of seizure in the entire population) and a specific
                 assessment of the drug-event-combination in the specific subpopulation (i.e. reports in
                 animals who also have renal impairment).


      8 https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-veterinary-good-

      pharmacovigilance-practices-vgvp-module-collection-recording-suspected-adverse-events-veterinary-medicinal-
      products_en.pdf

      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                                         Page 15/79

第 16 页

311   2.1.2. Methods for signal detection

312   Signals can arise from many different sources and may concern an array of different topics; hence
313   different methods may be needed to ensure that all relevant signals are detected. Signal detection
314   benefits from the use of a combination of quantitative and qualitative methods.

315       •    Quantitative methods are mostly used to detect signals in adverse event databases and
316            examples include; use of disproportionality measures, counting of reports, trend analyses and
317            other forms of mathematics/statistics applied to data. In some circumstances, quantitative
318            methods may also be applied in a limited manner to other signal sources. For example, trend
319            analyses of (social) media reports, scientific publications or other external information sources
320            may help identify potential emerging safety concerns requiring further evaluation.

321       •    Qualitative methods are based on review and interpretation of non-numerical information, e.g.
322            screening of case narratives or abstracts of scientific literature. They are often applied during
323            detection of signals arising from other sources than adverse event databases. However,
324            qualitative methods may be applied during signal detection in databases as well, although
325            caution should be taken to not cross over to signal validation (see section 2.3). During signal
326            detection, qualitative review should focus on identifying potential signals and more detailed
327            evaluation should be left for the validation and assessment steps.

328   Following detection, it is important to prioritise signals before moving on to validation (see section
329   2.2).

330   Before initiating signal detection, prior knowledge about the following aspects is expected: product
331   information, the mechanism of action of the product/substance in question, the outcome of previous
332   signal management activities and any other safety-related activities or procedures and any other
333   relevant pharmacovigilance data of which the MAH can reasonably be expected to be aware.

334   2.1.2.1. Signal detection in adverse event databases

335   Signal detection in adverse event databases should generally be performed at the VeDDRA level of
336   preferred terms (PTs).

337   However, it may occasionally be appropriate to perform signal detection at a higher level (HLT or SOC)
338   (see example 2). Conversely, there are situations where it may be relevant to stratify into LLT level
339   because certain LLTs belonging to a PT are already listed in the product information (see example 3)
340   (see also sections 2.2.1.6 and 2.2.1.8 on signal prioritisation and section 2.3.1.2 on signal validation).
341   The VeDDRA system is structured around organ classes, but sometimes signals may concern
342   ‘syndromes’ or collections of clinical signs from different organ systems, or there may be more than
343   one way to code the same event, leading to a need for combination of several terms to catch all
344   relevant reports. In such situations, it may be necessary to combine several similar PTs or LLTs from
345   different SOCs into one signal to allow for detection of broader signals or account for differences in
346   coding of reports (see example 4).

347   Whether there is a need to broaden or narrow a particular search at the signal detection stage will
348   need to be determined based on the clinical picture on a case-by-case basis.

349   It is generally not advised to combine different species in the same signal. However, there may be
350   situations where this can be relevant (e.g. product use errors, prescription errors, etc.).




      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                              Page 16/79

第 17 页

           Examples

           2:    Since similar events may be coded differently, it may be relevant to consider a high level
                 group of VeDDRA PTs together, e.g. an event where the animal experienced local swelling
                 redness and pain at the injection site, may be coded with any combination of ‘injection site
                 erythema’, ‘injection site inflammation’, ‘injection site lesion’, ‘injection site mass NOS’,
                 injection site pain’ and/or several other PT’s, leading to a need for analysis of all ‘Injection
                 site reactions’ (HLT) together.

           3:    In a situation where the PI includes the LLT ‘enteritis’, it may be relevant to monitor other
                 LLTs belonging to the PT ‘enteritis’, either because they are more specific than what is
                 currently in the PI, e.g. ‘lymphoplasmacytic enteritis’, or more serious, e.g. ‘haemorrhagic
                 enteritis’.
                 Or, it may be relevant to monitor only specific LLTs out of the 102 LLTs belonging to the PT
                 ‘Lack of efficacy’ due to properties of the product. For example, it may only be necessary to
                 monitor ‘Lack of efficacy – Parvovirus’ and the unspecified LLTs ‘Lack of efficacy NOS’ and
                 ‘Partial lack of efficacy’ in case of a vaccine against parvovirus.

           4:    ‘Pancreatitis’ (digestive tract disorders SOC) may be combined with ‘Elevated pancreatic
                 enzymes’ (investigations SOC), or
                 ‘Reluctant to move’ (systemic disorders SOC) may be combined with ‘Lameness’ and ‘Joint
                 pain’ (musculoskeletal disorders), or
                 PT’s from the SOC ‘Application site disorders’ may be relevant to combine with PTs from the
                 SOC ‘Ear and Labyrinth disorders’ for an ear product, or
                 PT’s ‘Anaemia’, ‘Haemolytic anaemia’, ‘Immune mediated haemolytic anaemia’ and ‘Aplastic
                 anaemia’ for a signal on anaemia to capture all relevant cases.



351   Number of cases or reacting animals

352   During signal detection in databases the first parameter to consider would be number of cases
353   reporting the different VeDDRA terms, both cumulatively from the date of authorisation and/or in a
354   specified time period (e.g. since the data lock point of the last annual statement). Special attention
355   should be paid to what is most commonly reported for the product and any observed changes in such
356   patterns over time. The number of reacting animals should also be taken into account. For reports in
357   species usually kept in herds, the number of reacting animals should be interpreted together with the
358   number of cases (representing independent herds), as a large number of reacting animals from a
359   single herd may provide different information from similar events reported across multiple independent
360   herds.

361   VeDDRA terms with a high cumulative number of reported cases or a large number of reacting animals
362   should be considered as potential signals. Such VeDDRA terms may not necessarily present with
363   disproportionate reporting due to masking effects (see next sub-section), yet their volume of reports
364   can still be clinically relevant and warrant further assessment.

365   Disproportionality in reporting

366   The concept of disproportionality in reporting is mostly used when analysing case reports in adverse
367   event databases such as the UPhV-database (EVV-DWH) or the MAHs’ own safety databases. When an
368   adverse event is described as having ‘disproportionate reporting’, or as being ‘disproportionately
369   reported’ in general, it means that the drug/product event combination is reported more often than



      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                                Page 17/79

第 18 页

370   expected; i.e. the adverse event in question is reported more often in combination with the
371   product/drug in question compared to the average for all other products in the database.

372   The difference between the concept of ‘disproportionate reporting’ in general and the specific concept
373   of a ‘Signal of Disproportionate Reporting’ (SDR) is that the latter reaches a pre-defined ‘level of
374   disproportionality’. The criteria used to define an SDR are often specific to the database used for signal
375   detection and the method used to calculate disproportionality, which is why it is important to document
376   which database an SDR was detected in and the specific criteria/threshold values and method for
377   calculation of disproportionality it uses.

378   It should be noted that disproportionate reporting does not automatically imply causality. It is a
379   mathematical tool flagging up product-event pairs and disproportionate reporting can be seen for a
380   product-event pair with no causal association, while it may be absent for a product-event pair with a
381   well-established causal association (see also section about factors influencing the ROR below).
382   Detection of disproportionate reporting should therefore always be combined with qualitative review of
383   data during further assessment.

384   Methods of calculating disproportionality

385   When performing signal detection, disproportionality measures should generally be evaluated based on
386   cumulative data, but comparison of disproportionality between different time periods may be relevant
387   to identify trends and changes in disproportionality.

388   Disproportionality can be calculated using different methods such as Proportionate Reporting Rate
389   (PRR), Information Component (IC025) or Reporting Odds Ratio (ROR). The three mentioned methods
390   are all based on a 2x2 contingency table:

                                                    Reports of adverse event of interest   Reports of other adverse events

       Reports with drug/product of interest                           a                                  b

       Reports with other drugs/products                                c                                 d


391      Table 1: 2x2 contingency table


392   Note that the contingency table only states the number of reports and therefore does not take into
393   account that reports may have multiple reacting animals. Therefore, in species with herd level reports,
394   it may be necessary to apply other quantitative measures during signal detection such as number of
395   reacting animals or use more qualitative methods such as case review.

396   The UPhV-database (EVV DWH) uses ROR for calculation of disproportionality. ROR can be calculated
397   from the contingency table using a simple formula:
                 𝑎𝑎/𝑐𝑐
398   𝑅𝑅𝑅𝑅𝑅𝑅 =
                 𝑏𝑏/𝑑𝑑


399   If ROR is precisely 1, the adverse event of interest is reported with the drug/product at a rate identical
400   to the average for all products in the database. Consequently, if ROR is greater than 1, there is
401   disproportionality in the reporting. However, the ROR alone is not sufficient to judge whether an
402   association between a product and an adverse event is statistically robust. This is why 95% confidence
403   intervals (CIs) are calculated and displayed as ROR(–) and ROR(+). A useful rule of thumb is based on
404   the lower bound:

405   If ROR(–) > 1, the association is considered statistically significant, meaning the reported event occurs
406   more frequently than expected.


      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                                       Page 18/79

第 19 页

407   Other measures of disproportionality may be used by MAHs during signal detection. MAHs should
408   justify and document their choice of method(s) and include a description of those methods, including
409   the underlying principles and any criteria and thresholds applied.

410   Criteria for SDRs in the UPhV-database (EVV DWH)

411   In EVV-DWH, an SDR is defined as a signal fulfilling all the following criteria:

412       •    ROR ≥ 2

413       •    ROR(-) ≥ 1

414       •    Cumulative number of reports ≥3 for Medically Important Terms (MI terms, see section
415            2.2.1.3) or ≥5 for all other VeDDRA terms.

416   SDRs can be a useful tool to detect signals, but not all VeDDRA terms highlighted as SDRs are
417   necessarily signals; for example, terms highlighted as SDRs may already be listed in the product
418   information (see sections 2.2.1.6 and 2.2.1.8 on signal prioritisation and section 2.3.1.2 on how to
419   determine coverage by the PI during signal validation). In addition, there are factors potentially
420   affecting disproportionality which should be considered, as described below. Further signal validation
421   may also end in non-validation of an SDR (see section 2.3 on signal validation). See also ‘Veterinary
422   Union Pharmacovigilance Database – Best Practice Guide’ 9 and ‘Veterinary Pharmacovigilance EVVET -
423   Data Warehouse user manual’ 10.

424   Factors affecting disproportionality

425   Certain factors beyond true disproportionate reporting may affect disproportionality. When such factors
426   lead to an increase in the ROR, this is referred to as ‘artificial inflation of disproportionality’.
427   Conversely, when such factors lead to a decrease in the ROR, it is referred to as ‘masking of
428   disproportionality’. Many of these factors can affect the ROR in both directions depending on the
429   situation. It is therefore important to consider these factors on a case-by-case basis during signal
430   detection.

431   Such factors include, but are not limited to:

432       •    Stimulated reporting: This may occur e.g. in cases of media attention on a certain product or
433            adverse event or immediately following publication of new warnings. Stimulated reporting may
434            artificially inflate the ROR.

435       •    Increase in exposure (sales): Increased exposure may lead to increased disproportionality (i.e.
436            artificial inflation), although the reporting incidence remains stable.

437       •    Duplicate reports: A high number of duplicate reports in a database may both artificially inflate
438            or deflate disproportionality. If there is a high number of duplicates only on the specific term of
439            interest that would lead to an artificial inflation of the ROR, while the reverse situation (high
440            number of duplicates for other adverse events or other products) could lead to masking. In the
441            UPhV-database (EVV DWH) duplicates are considered to most often lead to inflation of the
442            ROR.

443       •    Co-prescription (bystander products): Drugs/products that are often prescribed with other
444            drugs with a more high-risk safety profile or to animals with many co-morbidities may
445            experience artificially inflated disproportionality measures.



      9 https://www.ema.europa.eu/en/documents/other/veterinary-union-pharmacovigilance-database-best-practice-

      guide_en.pdf
      10 https://www.ema.europa.eu/en/documents/other/evvet-data-warehouse-user-manual_en.pdf


      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                                       Page 19/79

第 20 页

446       •    Confounding by indication: When there is disproportionality of clinical signs which may be
447            related to the indication of the product/drug the ROR may be either artificially inflated or
448            masked. Artificial inflation occurs in a situation where signs of the underlying disease are
449            mistakenly reported as AEs, while masking occur in a situation where AEs are not reported as
450            they are falsely assumed to present signs of the underlying disease.

451       •    Rarity and common/general clinical signs:

452                 o    Rarity may artificially inflate ROR in certain situations; for example, for rare product
453                      types, disproportionality may be artificially inflated for certain VeDDRA terms which, by
454                      nature, are linked only to a small subset of products e.g. implant site reactions occur
455                      only with products that are implants. In such situations, it may make sense to also
456                      determine disproportionality in relation to a smaller subset of similar products rather
457                      than all products in the database. However, the robustness of calculations is
458                      compromised when based on very small datasets.

459                 o    Conversely, clinical signs (VeDDRA terms) that are non-specific and may have many
460                      causes, or signs often related to drugs or specific classes of drugs may be so widely
461                      reported on all products/drugs in the database, that differences become difficult to
462                      detect (masking). Hence, the ROR for an event which is commonly occurring for many
463                      other products but only occurs very rarely for the product of interest, may be masked
464                      by the large amounts of reports present for other products.

465       •    Composition of the database: If a database includes only a limited number of products, or
466            mostly a few specific types of products (e.g. mostly antiparasitics, mostly vaccines etc.) this
467            may lead to both artificial inflation and masking of events, depending on the situation. This is
468            very important to consider when MAHs perform disproportionality analyses in their own safety
469            databases.

470   These and any other potential factors which may affect disproportionality should be considered when
471   appropriate during interpretation of disproportionality in signal detection.

472   Screening of case narratives

473   Screening of case narratives (qualitative review) may be necessary in some cases, to determine if
474   there is a signal or not. For example, for signals concerning large flocks/herds of poultry or schools of
475   fish or other production animals, there may be few cases concerning very large number of animals,
476   leading to a need for review of the case to determine if a signal is present. Another example may be in
477   cases of more complex signals involving new aspects of known risks or concerning more specific
478   subpopulations or other special circumstances of the signal that cannot readily be identified through
479   quantitative methods alone. Sometimes, such complex signals are triggered from screening or
480   reviewing of case narratives during validation or assessment of other signals (see example 5).




      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                                Page 20/79

第 21 页

           Example

           5:    When reports of similar events are coded under different VeDDRA terms they may not
                 generate a clear quantitative signal, e.g. situations of syndromes or newly arising disorders,
                 where no precise VeDDRA terms exist yet, where there is no consensus on nomenclature in
                 the veterinary field, or where general knowledge of the condition may be low, can lead to
                 reports of varied clinical signs related to the syndrome/disorder rather than the diagnosis
                 itself. Review of the case narratives reveals that the events are described similarly, despite
                 differences in coding. Identification of such a recurring pattern may trigger further
                 investigation of a potential signal.

481

482   Identification of potential quality and batch-related issues through signal detection

483   Signals related to one or more specific batches of a VMP are often detected from adverse event
484   databases by recognition of certain patterns of reporting. Examples of important patterns to monitor
485   for in adverse event databases are included below:

486       •     Temporal or geographical clustering: A cluster of adverse event reports linked to the same
487             batch number within a short period or localised area is a key indicator of a potential
488             batch‑related issue (see examples 6-7).

489       •     Increased frequency of a specific adverse event associated with a single batch: An unusual
490             increase or clustering of reports of a particular adverse event associated with an individual
491             batch, compared to other batches or historic data, indicates a batch related issue (see
492             examples 8-9).

493       •     Signs of contamination or sterility failure: An unusual pattern or clustering of adverse events
494             suggestive of contamination or loss of sterility in the suspected VMP may indicate a quality
495             defect or batch-related issue (see examples 8 and 10-11).

496   The above list should not be considered exhaustive and other methods may be applied in addition to
497   these for detection of quality and batch-related issues.

498


           Examples

           6:    Multiple reports within 24–72 hours following administration of a specific batch.

           7:    Reports originating from the same region or distributor, all citing the same batch.

           8:    Higher frequency of anaphylactic reactions linked to a specific batch.

           9:    Sudden increase in ‘lack of efficacy’ reports linked to a specific vaccine batch.

           10: Several reports, associated with the same batch, describe injection-site abscesses, swelling
                 and local infections occurring shortly after administration. Although the individual events
                 differ, the clustering of reports concerning a single batch may suggest contamination or loss
                 of sterility and warrant further investigation.

           11: Injection‑site infections emerging across multiple animals after use (of the same batch).




      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                               Page 21/79

第 22 页

499   2.1.2.2. Monitoring of scientific literature:

500   Monitoring scientific literature is part of the signal management process 11. Its purpose extends beyond
501   searching for adverse event reports and it should be considered a tool to keep up with current scientific
502   knowledge.

503   Monitoring of scientific literature usually involves performing searches for literature in databases and
504   specific journals if applicable and/or setting up automatic notifications on such platforms. The MAH
505   should establish the most relevant source(s) of published literature for each product. In order to
506   narrow down the search, relevant filters should be applied.

507   Monitoring of scientific literature is ideally performed on active substance level 12. Active substances
508   may have several different names and/or spellings, which should be taken into account when
509   performing literature searches; it is recommended to leave out names of salts (e.g. 'hydrochloride’). In
510   certain cases, it may make sense to also monitor closely related active substances (e.g. prednisone,
511   prednisolone and methylprednisolone), while for vaccines, it may be necessary to broaden the search
512   strategy to include terms related to the vaccine’s disease indication and relevant immunopathological
513   mechanisms, rather than relying exclusively on specific antigen names. Further filters may be applied,
514   but care should be taken to avoid narrowing the search too much.

515   Consideration should be given to scientific literature concerning potential environmental concerns
516   related to the active substance of the VMP or its metabolites as well as concerns regarding resistance
517   for antimicrobials and antiparasitic agents as these issues are difficult to detect through adverse event
518   reporting alone.

519   Once search results have been retrieved, an initial screening of abstracts and/or the whole article
520   should be performed in order to determine if the article in question is relevant to the product or the
521   active substance(s) of the product and contains information on safety or (lack of) efficacy which is
522   either new or may represent a new aspect of a known risk (e.g. frequency, outcome, further
523   characterisation etc). Thorough assessment of methods and validity of the articles is not necessary
524   during signal detection but may be applied during validation (see section 2.3.1.3).

525   2.1.2.3. Monitoring of other sources

526   Although pre-emptive monitoring is not possible for all potential alternative sources of signals (e.g.
527   spontaneous communication directly to the MAH), others (e.g. social media) are often monitored to
528   some extent as part of the collection and recording of adverse events. There may be situations, where
529   the information detected from other sources (see also sections 2.1.1.2 - 2.1.1.4) is not suitable for
530   creation of AERs to be entered into the UPhV-database, but may in itself constitute a signal trigger (i.e.
531   justify further investigation). Examples of additional sources which may be monitored are:

532       •    Non-peer-reviewed literature sources; e.g. public media targeting veterinarians or other animal
533            professionals in the countries of authorisation, national media in the countries of authorisation,
534            etc.

535       •    Social media; particularly the MAH’s own social media platforms.

536       •    Relevant websites or online forums, e.g. websites of EMA, NCAs or the MAHs own website.

537       •    Relevant veterinary or other scientific conferences.




      11 Article 81(1) of Regulation (EU) 2019/6
      12 Article 13(3) of CIR (EU) 2021/1281


      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                             Page 22/79

第 23 页

538   Pharmacovigilance staff should be sensitised to treat such information, when becoming aware of it, as
539   a potential signal trigger. It is recommended to include this in internal process documents for e.g.
540   monitoring of social media. The reasoning for it to be treated as a signal trigger should be recorded as
541   well as the date it was decided that the known information should be looked into further (and hence
542   classified as a trigger).

543   2.2. Signal prioritisation

544   Signal management should utilise a risk-based approach proportionate to the identified risk5. It is
545   therefore important to have an established and documented process of signal prioritisation throughout
546   the process2.

547   Signal prioritisation should be a continuous process throughout all steps of the signal management
548   process and is often carried out in parallel with each step. In many cases, signals may move directly
549   from detection through the validation phase and sometimes even through the assessment phase.
550   However, where multiple potential signals are identified simultaneously, prioritisation may be
551   necessary to ensure that the signals with the greatest potential impact on safety are progressed to the
552   next stage. If a potential signal is not prioritised at this point in time, the potential impact on safety
553   should be carefully considered. Pharmacovigilance alerts should always be prioritised.

554   Signal prioritisation during and following signal detection is essential to decide:

555       1. Which signals to start a validation on first,
556       2. Their urgency, both in general and in relation to other signals,
557       3. The extent of continued monitoring of the issue in the future.

558   Rationale behind prioritisation of signals should be documented.

559   2.2.1. Factors to consider during prioritisation

560   The factors listed in this section can help determine impact on overall safety, as well as urgency of the
561   signal and should be considered during prioritisation. Not all factors listed in this section may be
562   relevant for all signals during all steps of the signal management process, e.g. due to lack of
563   knowledge, or because another factor already determined the conclusion on the prioritisation.




      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                               Page 23/79

第 24 页

564
565      Figure 3: Decision tree for prioritisation during signal detection
566      Priority is determined by weighing impact on safety against the strength of evidence. All three exist on a
567      continuum. Safety should always be weighed highest.

568

569   2.2.1.1. Pharmacovigilance Alerts (PhV Alerts)

570   First and foremost, it is important to determine whether a potential signal could be a PhV Alert. A
571   Pharmacovigilance alert is defined as any suspected unexpected serious risk which may require urgent
572   regulatory action and communication by the MAH or the competent authorities as referred to in Article
573   129, Article 130 and Article 134 of Regulation (EU) 2019/6.

574   When a MAH becomes aware of a PhV Alert from any source, they should notify the competent
575   authority(ies) of the Member State(s) where the VMP is authorised or the Agency in case of centrally
576   authorised products. This should be done as soon as possible and no later than 3 working days after
577   establishing that a validated signal or a safety issue from any source constitutes a PhV Alert. See also
578   section 3.1.3.

579   In some cases, PhV Alerts may concern or involve a quality issue, or recalls of specific batches may be
580   necessary. However, a batch recall in itself, i.e. without evidence of a safety risk, is not considered a
581   PhV Alert.

582   See examples 12-16 of what may be considered PhV Alerts and examples 17-18 of what is not a PhV
583   Alert.




      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                                      Page 24/79

第 25 页

           Examples of potential Pharmacovigilance Alerts

           12: Major safety issues identified in the context of ongoing or newly completed studies, e.g. an
                 unexpected increase in rate of fatal or life-threatening adverse events. Where applicable,
                 separate (national) regulatory reporting requirements for studies should also be considered.

           13: Major safety issues identified from any source, which may lead to considering a
                 contraindication, a restriction of use of the VMP or its withdrawal from the market.

           14: Major safety-related regulatory measures outside the EU, e.g. a restriction of the use of the
                 VMP or its suspension.

           15: Major negative impact on the environment possibly caused by the use of a VMP.

           16: Increased level of residues in food-producing animals that may represent a safety concern
                 for humans. For example, detection of residues exceeding the MRL in cases where the
                 approved withdrawal period has been respected.


           Examples that should not be considered a Pharmacovigilance Alert

           17: Events that are associated with the use of a veterinary medicinal product in humans as part
                 of a suicidal attempt are not considered Pharmacovigilance Alerts. However, repeated
                 reports of suicidal attempts or emerging patterns indicating an unusual association between
                 a specific VMP and the adverse event may constitute a potential signal and should be
                 evaluated through the signal management process.

           18: New safety information related to quality defects or suspected falsified medicinal products
                 which might influence the evaluation of the benefits and risks of the VMP. These should be
                 notified in accordance with quality defect processes.


584   2.2.1.2. Safety (for the animal, user or environment):

585   For all remaining potential signals, the main focus during prioritisation should always be placed on the
586   risk to safety (for the animal, user or the environment). Some signals are likely to affect the benefit-
587   risk balance of a product more than others, if a causal association is considered possible in the end.
588   This is most often correlated with the seriousness and severity (see section 2.2.1.4) of the clinical
589   sign/disorder, but other factors may also come into play, such as size of the affected population and
590   properties of the signal itself; e.g. number of cases and affected animals already reported, number of
591   fatal cases etc. (see example 19).

592   The Medically Important Terms list (MIT-list, see section 2.2.1.3) is a useful tool when assessing
593   seriousness and severity of a signal during the signal management process. However, the specifics of
594   the signals should always be considered (see example 20).

595   The expected extent of future risk minimisation measure(s) arising from the signal may be considered
596   for guidance, as this is usually related directly to patient safety (see example 21).

597   The remaining aspects in this section (2.2) can also be considered but should always be secondary to
598   overall safety in the decision-making when prioritising potential signals for validation and further
599   assessment.




      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                             Page 25/79

第 26 页

           Examples

           19: A validated signal of acute renal failure which appears to occur in the entire target
                 population (i.e. not only in a subset of the population), that already has many reported
                 cases and a high number of fatal cases, would appear more urgent to assess for causality
                 compared to a validated signal of mild injection site inflammation occurring in a specific
                 breed, with no fatal cases. Both signals will need to be assessed, but the first is likely to
                 affect patient safety the most, if causality with the product is found to be confirmed.

           20: The MI-term ‘Anorexia’ may cover signals of great severity and/or seriousness, but could
                 also concern less severe/serious cases of mildly lowered appetite and further assessment of
                 a validated signal of severe ‘Anorexia’ in a species that is sensitive to sequela from anorexia
                 should be prioritised higher than assessment of a validated signal of mildly lowered appetite
                 in a less sensitive species.

           21: The following questions may be considered regarding potential future risk minimisation
                 measure(s):
                 If the events of the signal are concluded to be causally associated to the product, what
                 actions would that necessitate?
                 Would the product information need amendment and to what extent? Addition of adverse
                 reactions? Warnings or precautions? Additional monitoring advice? Relative or absolute
                 contraindications?
                 Could there be a need to disseminate immediate information through Direct Animal
                 Healthcare Professional Communication (DaHPC or ‘Dear Doctor’-letter)?
                 Or is it serious enough that a suspension or revocation of the marketing authorisation may
                 be considered?


600   2.2.1.3. VeDDRA Medically Important Terms (MIT)

601   The MIT list comprises VeDDRA PTs that correspond to medical conditions which are commonly
602   involved in suspected adverse events across different pharmacological or therapeutic classes, or which
603   are considered medically important independently of any established causal association with a
604   veterinary medicinal product, due to their seriousness or potential impact on animal health or welfare,
605   public health, user safety or the environment.

606   How to interpret and apply the MIT list in signal management:

607   Medically Important Terms (MITs) in veterinary pharmacovigilance are intended to function as a
608   prioritisation tool within signal detection and signal management activities. These events represent
609   medical concepts that require enhanced attention, prioritised assessment and timely regulatory follow-
610   up, in line with a proportionate pharmacovigilance approach.

611   In food-producing animals, MITs additionally include VeDDRA PTs that may be associated with
612   significant herd- or flock-level consequences (e.g. substantial productivity losses, reproductive
613   impairment or increased mortality). Where such effects reflect or accompany medically important
614   safety concerns, they justify prioritisation within signal detection, validation and assessment activities.

615   For events occurring in humans, all reports are regarded as medically important and should therefore
616   be handled as MITs for the purposes of prioritisation and signal management, irrespective of the
617   reported clinical term, seriousness classification or outcome.




      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                                Page 26/79

第 27 页

618   All events that are reported as ‘parent-offspring’ events should be considered medically important and
619   particularly any congenital conditions reported in this setting.

620   Malignant neoplastic conditions and neoplastic conditions which otherwise have a serious impact on
621   animal health and welfare should be considered medically important on a case-by-case basis.

622   Detected signals involving MITs should generally be prioritised particularly in the following situations:

623       •    Where they fulfil the criteria of a signal of disproportionate reporting (SDR) in DWH.

624       •    Where an unusual or unexpected increase in reporting frequency or number of affected animals
625            is observed.

626       •    Where there is evidence of increased severity or a change in outcome (compared to the
627            product information), such as an increase in fatal cases.

628   2.2.1.4. Severity and/or seriousness

629   Severity and seriousness are usually defined at case level. Here, severity refers to the intensity of an
630   adverse event, e.g. mild, moderate or severe, but severity does not express anything about the
631   medical significance of the event itself. Seriousness of an event is linked to outcome e.g. whether an
632   event was fatal, led to hospitalisation and/or long-term harm to the patient (see example 22).

633   While general criteria for seriousness can be found in the VICH GL24 (Pharmacovigilance of Veterinary
634   Medicinal Products: Management of Adverse Event Reports (AERs)), it is not possible to establish
635   general criteria for severity, as that is affected by the sign or disorder considered.

636   Both seriousness and severity may be used to prioritise signals. Seriousness can be evaluated by
637   screening for fatal cases, number of cases leading to full recovery and in some cases by clinical
638   judgement of the VeDDRA term itself (see example 23). The MI terms described in section 2.2.1.3
639   above may provide guidance in the evaluation of seriousness and severity.
640   Severity can sometimes be estimated by looking at reported LLTs (i.e. if it is the more or less severe
641   LLTs belonging to the PT that are mostly reported), or duration of the event, but many times a
642   screening of narratives is necessary to evaluate whether e.g. the PT ‘Anorexia’ covers a transient
643   partial loss of appetite or a more severe case of complete anorexia for a prolonged period of time.

644   Signals where the majority of the reported events are considered serious should be prioritised over
645   signals concerning less serious events, although rarity of the event should also be considered here (see
646   section 2.2.1.5).

647   Similarly, signals reporting more severe events should be prioritised higher compared to signals
648   reporting mild versions of the same event. Severity will, however, always need to be weighed against
649   seriousness and number of reports/reacting animals and potentially other factors, when comparing
650   different signals.




      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                             Page 27/79

第 28 页

           Examples

           22: For example, pruritus may be mild, moderate or severe, but a severe case of pruritus may
                 still not always be a serious case – if the animal recovered on its own with no long-term
                 sequelae. Conversely, severe heart failure is usually linked to serious outcome and even
                 ‘mild’ heart failure may be considered serious as it is likely to have a long-term negative
                 effect on the patient. Furthermore, a severe hypersensitivity reaction is usually serious,
                 while a mild hypersensitivity reaction is usually not. Hence severity and seriousness are
                 sometimes linked and sometimes not.

           23: For example, ‘heart failure’ can be assumed to be more serious in general, compared to e.g.
                 ‘injection site pain’.


651   2.2.1.5. Number of reported events and effect on special populations

652   Signals with higher numbers of reports and/or reacting animals or signals with increasing numbers
653   should have a higher priority. However, this should, as a minimum, be weighed against seriousness
654   and severity and other factors may come into consideration as well.

655   Signals affecting certain special populations e.g. pregnant animals, very young animals, or animals of
656   food-producing species that are close to slaughter may generally be prioritised, albeit with
657   consideration to potential off-label use (see section 2.2.1.11). Conversely, signals affecting a very
658   small subpopulation of animals, e.g. animals with a specific uncommon co-morbidity, may be
659   prioritised lower if there are other, more urgent signals to perform validation on.

660   2.2.1.6. Novelty

661   Novelty of the information may also be considered in the sense that it will often be more important to
662   progress with potential signals which may represent completely new information (e.g. a new adverse
663   event for the product) rather than signals concerning further characterisation of an already known
664   adverse event (new aspect of a known adverse event). The evaluation of novelty should, however, be
665   secondary to the evaluation of patient safety e.g. a potential signal that changes an already known
666   event from ‘mild and transient’ to ‘potentially life-threatening and/or chronic’ may affect patient safety
667   more than a new adverse event that in and of itself is mild and non-serious.

668   2.2.1.7. Preventability

669   One of the main aims of the entire signal management process is to mitigate the risks of treatment
670   with VMPs as much as possible. Any knowledge on preventability of the clinical signs/disorders or the
671   most severe outcomes can be taken into consideration during prioritisation. If a serious adverse effect
672   or outcome is known to be easily preventable, the information is of high value, as the benefit of
673   treatment will remain, while the risk is mitigated. However, preventability should not be regarded as a
674   decisive criterion for prioritisation and should be considered alongside other factors relevant to the
675   potential impact of the signal.

676   2.2.1.8. Potential signals concerning VeDDRA terms listed in the SPC

677   Known adverse events of a product are generally listed in section 3.6 of the SPC, while additional
678   information contributing to the description of adverse events as well as advice regarding risk mitigation
679   may also be found in sections 3.3 and 3.5. Information relating to efficacy and lack thereof is usually
680   included in section 3.4. It should be noted that adverse events are included in the SPC at VeDDRA LLT

      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                              Page 28/79

第 29 页

681   level, while signals are usually detected at PT level. Therefore, when a signal is detected at PT level, it
682   may be necessary to review the reported LLTs of cases to determine whether the reported events are
683   already adequately covered by the SPC or whether they represent a new or insufficiently characterised
684   aspect of the risk.

685       1. Monitoring of adverse events that are already listed with the exact wording in SPC section 3.6
686            should generally not be prioritised, with the exception of certain specific situations and factors,
687            where potential signals on listed events should undergo further prioritisation as normal:

688                 a) Signals concerning increased frequency, both sudden and gradual.

689                 b) Signals for VeDDRA PTs that include an LLT listed in the SPC, but also include LLTs
690                      considered more severe/serious in nature, or more specific, compared to the listed LLT.
691                      In these cases, monitoring of such LLTs should still be part of routine monitoring (see
692                      section 2.1.2.1 and 2.3.1.2 for further guidance).

693                 c)   Signals concerning a change in outcome towards more a severe outcome compared to
694                      what is described in the SPC, e.g. a rise in fatal cases.

695                 d) Signals further characterising the already known risk where the additional information
696                      may impact the understanding, management or communication of that risk.

697       2. Even if certain VeDDRA terms are not explicitly included in section 3.6 of the SPC it may be the
698            case that the suspected adverse event is already adequately covered by the text included in
699            the product information. If so, they should be handled as described in point 1 above.

700   Further guidance on how to determine whether a potential signal is adequately covered by the SPC is
701   provided in section 2.3.1.2.

702   2.2.1.9. Other previous knowledge on subject

703   Previous knowledge on the subject of the signal includes knowledge from previous signal validations
704   (irrespective of outcome), previous signal assessments, knowledge from previously assessed clinical
705   trials or any other procedure on the product in question including the initial authorisation procedure.
706   For example, a signal validation performed recently, which led to non-validation of the signal, may lead
707   to not prioritising the signal when detected again if the number of new cases received since then is
708   low. Conversely, in a situation where new data has been received and a causal association was highly
709   suspected in a recent signal assessment, but the evidence was not sufficient at the time of the
710   assessment, such previous knowledge may lead to prioritisation of the signal.

711   Knowledge from other products with the same active substance or with an active substance in the
712   same drug class may also be considered. For example, if the event is listed in the PI of another product
713   with the same substance, it may lead to increased suspicion of a potential causal association and
714   prioritisation of the signal.

715   2.2.1.10. The signal trigger

716   The signal trigger may in certain circumstances influence prioritisation. For example, in cases of
717   intense media interest, it may be of interest to the public and the MAH themselves to prioritise such a
718   signal, despite other factors. In other cases, a signal triggered from social media discussions with no
719   corroborating evidence from other sources, e.g. adverse event reports, product complaints or
720   literature, may not be prioritised. For example, discussion about lack of efficacy circulating on social
721   media, while there are no actual adverse event reports on lack of efficacy received in the period of
722   concern.

      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                              Page 29/79

第 30 页

723   In other cases, the strength of evidence of a source may factor into the decision e.g. a signal triggered
724   from a newly published double-blinded clinical trial indicating a new risk may be prioritised higher than
725   if the same signal was identified in an adverse event database.

726   2.2.1.11. Special situations

727   Batch-related issues

728   If a batch-related issue is detected from the signal management process (i.e. is a potential cause of
729   reported adverse events or lack of efficacy), it should be considered a potential/validated signal.
730   Batch-related issues which are not related to a detected signal (e.g. if the faulty batches never reached
731   end users or there were no reports related to the affected batches), do not need to be considered as
732   signals and should follow the process related to quality defects 13. If there is suspicion of a batch-
733   related issue involved in a signal, it should be considered whether the issue could be a PhV Alert (see
734   sections 2.2.1.1 and 3.1.3).

735   Batch‑related issues, such as those arising from manufacturing deviations, quality defects, stability
736   failures or supply chain problems, are generally considered high‑priority due to their potential to affect
737   large numbers of animals within a short timeframe and their preventable nature. The criteria explained
738   in section 2.2.1.4 regarding seriousness and severity of the events should be taken into consideration
739   during prioritisation of batch-related issues.

740   Signals involving off-label use, overdose or medication errors

741   The obligation to perform pharmacovigilance extends to include use outside the terms of the marketing
742   authorisation (i.e. off-label use, overdose or medication errors) 14.

743   The following signals in non-target species should always be prioritised:

744       1. Signals concerning user safety, i.e. occurring in humans, should always be prioritised and all
745            VeDDRA terms are considered MI-terms in humans.

746       2. Signals concerning serious consequences of accidental exposure (a medication error) in non-
747            target species.

748       3. Signals concerning serious and severe adverse events in non-target species, where the
749            expected risk minimisation measures following a conclusion of a possible causal association
750            would involve a need to at least inform the public (see examples 24-25).

751   Signals involving some extent of use outside the terms of the marketing authorisation should generally
752   be prioritised in a similar way to all other signals and the evaluation of the role of non-authorised use
753   will usually be performed at a later stage.

754   In situations where there is knowledge of widespread use outside the terms of the marketing
755   authorisation for specific purposes, e.g. in a specific non-target species or for a specific off-label
756   indication in the target species, safety signals occurring in these circumstances should give rise to
757   further analyses of the signal(s) and considerations of whether it may be relevant to implement risk
758   minimisation measures in an attempt to reduce the off-label use to reduce the risk. For example,
759   safety signals where the majority of cases report use against a contraindication listed in section 3.3
760   may often not require prioritisation immediately. However, continued reporting of adverse events in




      13 https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/compliance-post-authorisation/quality-

      defects-recalls
      14 Article 11 of CIR (EU) 2021/1281


      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                                      Page 30/79

第 31 页

761   such cases should lead to concern that risk mitigation through a contraindication is not sufficiently
762   effective and thus may require further action from the MAH (see section 2.6 and example 26).

763   Signals specifically concerning previously unknown risks connected to overdose in the target species
764   can usually be prioritised below signals concerning use within the terms of the marketing authorisation.
765   However, as the MAH also has an obligation to keep the section of the PI concerning overdose up to
766   date with newest scientific knowledge, such signals cannot be dismissed with the argument of
767   overdose alone.

768   Signals concerning medication errors should be prioritised according to the risk the errors pose, as well
769   as preventability of the errors observed.

770   Signals receiving media attention

771   In some circumstances, signals that could cause/are causing media attention and/or public concerns
772   may deserve special attention. Prioritising further analysis of such signals may ensure a faster
773   conclusion (no matter the final outcome of the signal) and increase trust from the public.

774   Antimicrobial or antiparasitic resistance

775   Signals which may be a sign of antimicrobial/antiparasitic resistance should generally be prioritised.

776   Environmental risks

777   Signals may directly concern a risk to the environment. However, even for signals which do not
778   primarily concern the environment, it may be relevant to consider whether there could be
779   consequences for the environment. This is especially true for signals involving adverse events in an
780   animal or species other than the treated one, e.g. accidental exposure. Please also refer to section
781   2.3.1.3 on validation of environmental signals.

782   Signals with the primary topic of an environmental risk may arise from adverse event reporting,
783   scientific literature or other sources and should generally be prioritised. An additional environmental
784   aspect to a signal primarily focused on an adverse event would similarly increase priority.


           Examples

           24: A signal suggests that a serious adverse event may occur in a non-target species following
                 exposure to a veterinary medicinal product. Early recognition and discontinuation of
                 treatment appear to improve the clinical outcome. If confirmed, communication to
                 veterinarians and animal owners may be necessary to ensure prompt recognition and
                 intervention.

           25: Several reports describe severe neurological adverse events in a non-target companion
                 animal species following accidental exposure to a product intended for another species. If a
                 causal association is confirmed, a precaution may be added to SPC section 3.5 and the
                 corresponding section of the PL under the sub-heading ‘other precautions’ in accordance with
                 the QRD template for VMPs.

           26: A product contraindicates use in animals below a certain age, but serious adverse events
                 continue to be reported predominantly in that age group. This may indicate that the existing
                 risk minimisation measure (the contraindication) is insufficient and additional measures are
                 therefore implemented, e.g. strengthened wording of the contraindication, additional
                 warning added to the package or other measures as described in section 2.6.

785


      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                              Page 31/79

第 32 页

786   2.2.2. Impact on future prioritisation during ‘routine monitoring’

787   If a potential signal is not prioritised for immediate progression to validation, it will usually return to
788   ‘routine monitoring’ and should be considered again during subsequent signal detection activities. Such
789   signals may be re-detected and prioritised at a later time.

790   If a validated signal is not prioritised for immediate assessment, it should be subject to enhanced
791   monitoring until the signal assessment has been completed. Any new information received during this
792   time should lead to a new assessment of urgency.

793   Non-validated and refuted signals (see sections 2.3.2.2 and 2.5.1 respectively) usually return to
794   ‘routine monitoring’.

795   However, factors determined during prioritisation, prior signal validations or assessments may
796   influence future prioritisation during routine monitoring for both potential signals for which progression
797   to validation were previously deferred, previously non-validated signals and previously refuted signals
798   (see also sections 2.3.2.2 and 2.5.1, see examples 27 and 28 and figure 4):


           Examples

           27: A specific VeDDRA term has been determined to be biologically implausible during signal
                 detection and/or prioritisation. Future (routine) monitoring may have lower priority.

           28: A potential signal of low seriousness and severity was not prioritised for immediate
                 progression to validation due to presence of other signals determined to have a greater
                 impact on overall safety. However, a causal association could be possible based on
                 mechanism of action. The issue should then be given higher priority if re-detected during
                 routine monitoring.




      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                                Page 32/79

第 33 页

799
800      Figure 4: Impact on future prioritisation of previously detected signals
801      Previous status: Refers to the outcome of previous prioritisation validation or assessment of the same signal,
802      depending on how far the signal came in the signal management process.
803      Previously detected signals, which led to risk minimisation measures, are not covered by this figure.

804

805   2.3. Signal validation

806   Once a signal has been identified through the signal detection process and has been prioritised for
807   validation, the next step in signal management is to conduct the signal validation. Signal validation is
808   an initial screening of the data that triggered the potential signal, with the aim of determining whether
809   the signal is supported by information of sufficient quality and substance to justify further assessment.
810   Therefore, signal validation is not intended to determine causality. At this stage of the signal
811   management process a causal association is only suspected and further assessment is needed to
812   conclude on causality.

813   When to perform a signal validation on a detected signal is determined through signal prioritisation
814   (see section 2.2).

815   The outcome of signal validation is either to ‘validate’ the signal, or ‘non-validate’ the signal. All
816   validated signals should be further assessed (see section 2.4) and entered into IRIS 15 Veterinary Signal
817   Management (VSM), irrespective of the eventual conclusion (see sections 2.5 and 3.1).

      15 https://iris.ema.europa.eu/ - EMA’s online platform for submitting and managing regulatory and scientific procedures for

      medicines throughout their lifecycle

      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                                            Page 33/79

第 34 页

818   It is important to have an established protocol for signal validation. However, different steps might be
819   required for different signals depending on their origin. As a minimum, a documented process for
820   validation of signals originating from adverse event databases should be established and made
821   available for inspection.

822   All signal validations performed should be documented and recorded in a traceable manner and the
823   documentation should be sufficient to demonstrate the rationale and outcome of the validation during
824   inspections as well as what data the validation process was based on. See also section 5.

825   2.3.1. Methods for signal validation

826   The methods used to validate a signal may differ depending on the origin and other properties of the
827   signal. Signal validation is usually performed on the initial data present when the signal was detected
828   (the signal trigger). The process of validation is thus not meant to include searching for additional data
829   from other sources, except for in specific circumstances (see sections 2.3.1.1 and 2.3.1.3).

830   2.3.1.1. Initial considerations

831   During signal validation, clinical judgement should always be applied and signals which are biologically
832   implausible should be non-validated. Hence, the product should be able to reasonably cause the event
833   (see examples 29 and 30).

834   However, caution should be exercised as to not dismiss signals due to confirmation bias; i.e. signals
835   should not be non-validated simply because they are not considered to fit the known safety profile. Not
836   everything is discovered in clinical trials and it is important to stay open-minded and unbiased to
837   possible associations.

838   Additionally, a critical assessment of whether the reported events are similar enough to constitute a
839   signal may be necessary in some situations, while in others it may be relevant to consider whether the
840   initial signal needs to be expanded to e.g. cover several similar or medically linked VeDDRA terms in
841   the validation. Certain VeDDRA terms are very broad or non-specific and may encompass a variety of
842   disorders, while others overlap and may be used interchangeably by reporters leading to a need for a
843   combined validation (see examples 31 and 32).


           Examples

           29: A topical product with a well-established pharmacokinetic profile, known to have no or very
                 limited systemic uptake, is unlikely to be causally associated with a signal of ‘fracture’.

           30: A product not used in the ears would be unlikely to directly cause ‘tympanic rupture’.

           31: In case of a detected signal on a VeDDRA PT such as ‘carcinoma NOS’ the cases may all be
                 reporting the same or at least similar types of carcinomas, or they may be reporting
                 completely different carcinoma types, which would affect the decision on whether to validate
                 the signal.

           32: In case of a detected SDR on ‘gastrointestinal ulceration’ it may be relevant to also include
                 any additional cases reporting ‘intestinal perforation’ and ‘gastric perforation’.


844   2.3.1.2. Data screening

845   An initial verification of the data (most often case reports) should be performed. The verification
846   should, as a minimum, ensure that:

      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                               Page 34/79

第 35 页

847       •    There is a temporal association,

848       •    The adverse event is not already adequately described in the current product information,

849       •    The signal is not based on duplicate reports (which would artificially inflate the apparent
850            number of reports and any potential disproportionality).

851   Temporal association:

852   Temporal association is usually discussed using the term ‘time-to-onset’ (TTO). TTO is usually
853   expressed as the time period (in minutes/hours/days/weeks etc.) from initiation of treatment with the
854   product and until the first clinical signs of the event occur.

855   Presence of a temporal association means that the reported event(s) occurred after the time of the
856   first exposure to the VMP(s). Cases where the events occurred prior to the time of exposure do not
857   have a temporal association (also sometimes expressed as having a ‘negative TTO’). Such cases would
858   never be considered supportive of the signal, regardless of any other factor considered in future
859   causality assessment (see also section 2.4.2).

860   In addition to determining whether there is a temporal association, exclusion of cases with a very
861   unreasonable TTO can be considered, even when a temporal association exists. It should be
862   emphasised that the goal of the validation stage is not to evaluate causality and therefore also not to
863   evaluate the finer details of TTO in each case. However, there may be certain situations where TTO is
864   unrealistically long (e.g. anaphylactic shock occurs many months following a single administration of
865   an inhalant anaesthetic) or unrealistically short (e.g. cancer is diagnosed the day after the first
866   administration). The pharmacokinetic profile of the product needs to be taken into account when
867   evaluating these situations - some products are known to have a very short half-life and are usually
868   given as single administration only, while other products are used for longer periods of time or are
869   specifically designed to elicit a long-term effect or have special delivery systems prolonging the effect.

870   Description in the product information:

871   Known adverse events of a product are generally listed in section 3.6 of the SPC and section 7 of the
872   PL, while additional information contributing to the description of adverse events as well as advice
873   regarding risk mitigation may be found in sections 3.3 and 3.5 of the SPC and the corresponding
874   sections of the PL. Information relating to efficacy and lack thereof is usually included in section 3.4 of
875   the SPC and the corresponding section of the PL.

876   Even if certain VeDDRA terms are not explicitly included in the PI it may be the case that the
877   suspected adverse event is already covered by the text included in the product information.

878   It should be noted that adverse events are included in the PI at VeDDRA LLT level, while signals are
879   usually detected at PT level, therefore it may sometimes be necessary to check the reported LLTs of
880   the cases belonging to a given PT (see also section 2.2.1.8).

881   Furthermore, the product information for a generic or hybrid product should be kept in accordance with
882   the PI of the reference product 16. Therefore, potential signals which are already included in the PI of
883   the reference product should be non-validated. Instead, the generic MAH should submit a variation to
884   the terms of the marketing authorisation without undue delay, in order to rectify any inconsistencies.

885   In cases of doubt as to whether the suspected adverse event(s) is covered by the PI, focus should be
886   on the following:




      16 Article 18(6) of Regulation (EU) 2019/6


      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                             Page 35/79

第 36 页

887       •    Are the events of the potential signal more serious or severe in nature compared to the terms
888            already included in the PI? (see also section 2.2.1.4)
889   If the events of the signal are considered more serious compared to the terms included in the PI, the
890   events of the signal should not be considered covered by the current PI (see example 33).

891   Since one PT may include both more and less serious LLTs, situations may arise where a signal is
892   detected on a PT where one LLT is already listed. In such cases it would be necessary to check the
893   reported LLTs of the cases (see example 34).

894       •    Are the events of the potential signal more specific compared to the terms already included in
895            the PI?
896   If the events of the signal are more specific compared to the currently approved PI, this may be a
897   signal that would further characterise a known risk (i.e. a new aspect) or the signal may represent a
898   separate subgroup and should therefore not be considered covered by the PI in most cases (see
899   examples 35-36).

900   In these situations, the listed events should not be considered a reason to non-validate the signal on
901   their own. However, the clinical relevance of the signal should be evaluated and the relation to already
902   listed events may play a role in the prioritisation of signals (see section 2.2.1.6).

903   Since one PT may include both more and less specific LLTs, situations may arise where a signal is
904   detected on a PT where one LLT is already listed. In such cases it would be necessary to check the
905   reported LLTs of the cases (see examples 37-38).

906   There may be certain exceptions to this rule, e.g. if the PI already includes adverse events that
907   encompass other events in a way where additional specification may not provide useful information
908   (see example 39).

909       •    Does the potential signal constitute a new aspect of the already included term?
910   For example, is it a signal of potentially increased frequency or severity? Or potentially increased
911   frequency or severity in a subset of the target population (e.g. animals with certain comorbidities,
912   certain breeds, certain age groups, pregnant females etc.)? Would it constitute a change in duration or
913   outcome compared to what is currently described in the PI? To answer questions regarding frequency,
914   it would be relevant to check the rate of reporting against the estimated exposure of the VMP
915   (incidence of reported adverse events).

916       •    Are the events of the potential signal always linked to the terms included in the PI?
917   Some terms may be linked in some cases and not in others. For such situations, it may be needed to
918   review how many of the cases concern events related to the already listed event (see example 40).




      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                            Page 36/79

第 37 页

           Examples

           33: In a case where ‘Elevated creatinine’ is included in the PI, but the validation is performed on
                 a signal of ‘Acute kidney injury’, the signal would not be considered covered by the current
                 PI.

           34: In a situation where LLT ‘Elevated temperature’ is included in the PI and a signal has been
                 detected on the PT ‘Hyperthermia’, which the listed event belongs to. However, the cases
                 mostly report the LLT ‘Fever’. Since ‘Elevated temperature’ may include temperature
                 increases below the threshold of fever, a signal where the LLT reported is ‘Fever’ would be
                 considered more serious and more specific.

           35: If the currently approved PI lists ‘Injection site reaction’ and the signal undergoing validation
                 concerns ‘injection site necrosis’ this could be further specification of the risk.

           36: If the PI lists ‘Neoplasia’ and the signal concerns ‘injection site neoplasm’ that would further
                 specify the risk.

           37: In a situation where the LLT ‘Colitis’ is already listed in the PI and the cases turn out to
                 mostly report the specific illness of ‘Ulcerative colitis’ this would be considered to either
                 further characterise the risk, or it may represent a new risk.

           38: Similarly, if the PI lists ‘cardiac enlargement’ however the reported cases of the signal
                 mostly code ‘hypertrophic dilated cardiomyopathy’ this would be considered further
                 characterisation (specification) of the risk, as hypertrophic dilated cardiomyopathy is a
                 specific type of cardiac enlargement.

           39: If the signal undergoing validation concerns ‘injection site oedema’, but the PI already lists
                 ‘injection site inflammation’ in section 3.6, the added information of including ‘injection site
                 oedema’ may be considered negligible, since oedema is a well-known cardinal sign of
                 inflammation, despite oedema being more specific.
                 However, in the reverse situation, where ‘injection site oedema’ was the listed term,
                 ‘injection site inflammation’ should not be considered automatically covered by the PI, as
                 more clinical signs than oedema are usually connected to inflammation (e.g. warmth and
                 erythema).

           40: If ‘Hepatic failure’ is listed in section 3.6 of the PI, validation of a signal of ‘Jaundice’ may
                 focus solely on cases where non-hepatic causes of jaundice are suspected.



919   Duplicate reports:

920   In cases of doubt as to whether reports are in fact duplicates of each other or not, it is better to
921   consider the reports as unique.

922   It may also be relevant to consider the source of the reports; in situations where all reports originate
923   from the same reporter, it should be assessed whether there may be factors related to the reporter
924   which are more or at least equally likely to have caused the events (e.g. geographical, concurrent
925   treatments, prior disease history, handling of the products or animals, etc.). Signals concerning
926   medication errors, where all reports originate from the same reporter, can usually be non-validated.




      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                                Page 37/79

第 38 页

927   2.3.1.3. Special types of signals

928   Certain types of signals may need to be assessed differently and therefore other criteria may be
929   relevant during validation as well.

930   As mentioned in section 2.1.1, signals may arise from other sources than analysis of adverse event
931   databases. Often, such signals are detected using qualitative methods and, in some cases, they may
932   be considered validated based on the initial screening during signal detection.

933   If a signal has arisen from more than one source e.g. both a new published article and data from an
934   adverse event database, both sources should be verified using appropriate methods and considered in
935   the final decision on whether to validate the signal or not.

936   Signals arising from monitoring of scientific literature:

937   Validation of a signal arising from scientific literature may encompass an evaluation of the strength of
938   the article(s) or study/studies that triggered the signal but does not necessarily need to encompass
939   searching for additional data. Furthermore, presence of AE reports in adverse event databases
940   concerning the same term may be used to validate the signal where relevant.

941   Signals arising from media (including social media):

942   Signals arising from media attention or social media comprise a challenge during the validation
943   process, as the triggering information may not always be verifiable in nature. In such cases the
944   validation step may include considerations mentioned in the above sections 2.3.1.1 and 2.3.1.2,
945   combined with targeted signal detection in adverse event databases and scientific literature to see if
946   the signal can be verified through other sources.

947   Medication errors:

948   For signals (in animals) involving medication errors it is particularly important to consider whether the
949   reports originate from different (unrelated) sources. Signals of medication errors which can all be
950   traced back to the same source may be non-validated, if they are considered related to the specific
951   source rather than representing a general problem with the product. Furthermore, for reports of
952   medication errors it is particularly relevant to check whether the reported medication or product use
953   error is related to the investigated product, or to another product. Additionally, whether the medication
954   error has led to safety concerns and the severity and seriousness of any such concerns should be taken
955   into consideration, as well as the number of reports and reacting animals. Co-reported safety issues
956   may be checked against the PI.

957   Considering that many of the VeDDRA terms related to medication errors are rather broad, it may also
958   be important to identify patterns in the reported events; are they reporting similar types of errors or
959   completely different errors? In situations where no trend or pattern can be identified, the signal can be
960   non-validated.

961   Signals involving overdose:

962   When referring to overdose in pharmacovigilance, it is usually in reference to use of greater dosages
963   than what is approved (e.g. 20 mg/kg rather than the approved 10 mg/kg). However, depending on
964   the pharmacodynamic and pharmacokinetic properties of a drug (e.g. if accumulation is expected), it
965   may also be relevant to consider prolonged use as overdose in some situations.

966   It is necessary to evaluate at what level overdose becomes relevant to the assessment of the reported
967   events. For some products, a minor overdose may be irrelevant and should thus be evaluated on the
968   same ‘terms’ as non-overdose cases, while for others the therapeutic index is narrower and even a


      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                            Page 38/79

第 39 页

969   minor overdose is considered significant for the risk profile. Patterns of reported events may also differ
970   between different levels of overdose.

971   The MAH should also keep the product information up to date regarding clinical signs of overdose and
972   systematic exclusion of overdose cases at the signal detection stage is therefore not recommended.

973   Suspicion of batch-related risks:

974   For signals suspected to be tied to batch-related issues, case reports can be checked for presence of
975   batch-numbers as well as which precise batch-numbers apply. However, the basic principles of signal
976   validation should still be considered. In cases where batch-related risks are coupled to safety signals, it
977   is necessary to evaluate whether it could be a PhV alert.

978   Lack of expected efficacy (LEE):

979   When validating a potential signal of lack of efficacy, the data screening will need to be modified for
980   the purpose. If the signal originates from an adverse event database (i.e. is based on AE reports), the
981   cases may be screened for a temporal association in a similar manner as described above, but it will be
982   highly important to know the expected time-to-onset of expected effect as well as duration of the
983   expected effect to determine if there is a temporal association with potential lack of efficacy. In
984   addition to screening for temporal association, duplicate reports and whether lack of efficacy is already
985   described in the PI, it is usually important to assess which expected effect is reported as lacking and
986   whether this is actually an indication of the product. Furthermore, it may be assessed whether the
987   product was handled and used in accordance with the product information and whether the deviations
988   are likely to affect efficacy. In cases where LEE is already described in the product information, it may
989   be of relevance to check whether frequency has increased or whether there are new aspects to the
990   already described lack of efficacy.

991   Signals concerning a risk to the environment:

992   When validating a signal where the primary focus is a risk to the environment, it is important to
993   consider whether the signal can be traced back to use of the product or active substance in animals,
994   either in a specific or unspecific way. If a potential environmental risk cannot be led back to use of the
995   product in animals, it is not considered a signal (see examples 41-43).

996   Environmental signals should otherwise be validated using the same methods as described in sections
997   2.3.1.1 and 2.3.1.2.


           Examples

           41: Published scientific literature describing a toxic effect on the environment after experimental
                 exposure (e.g. pouring out the active substance with the purpose of studying the effect)
                 would not be considered a signal.

           42: Adverse event reports describing death of fish and plant life in a local pond after treated
                 dogs bathed in the water would be considered a signal.

           43: Detection of the active substance of a product in natural water sources; This is considered a
                 signal if the active substance is only commercially available as product(s) for use in animals,
                 since there would not be other reasonable sources than the product. However, if the
                 substance is also available from other sources, e.g. human medicinal use, pesticides, feed
                 additives etc., it would not be considered a signal as the presence in the environment may
                 be from these sources.



      Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
      Management
      EMA/522332/2021 Rev.1                                                                             Page 39/79

第 40 页

998   2.3.2. Outcome of signal validation

999   When finalising signal validation, the signal should be concluded as either validated or non-validated.

1000   2.3.2.1. Validated signal

1001   A signal is considered validated when the signal validation process has verified that the data triggering
1002   the signal is of sufficient quality and substance to justify a need for further analysis and the event(s) of
1003   the signal are not already adequately described in the product information.

1004   Validation of a signal does not imply that a causal association with the VMP has been established, only
1005   that the observations meet the criteria for a plausible hypothesis, with sufficient data to justify its
1006   progression to further analysis/assessment.

1007   Validated signals will need to be investigated further to assess causality with the product/substance
1008   (see section 2.4). All validated signals should be submitted to authorities through IRIS-VSM following
1009   assessment. The timeline of signal submission in IRIS depends on the outcome of the assessment (see
1010   section 3.1.2.2).

1011   2.3.2.2. Non-Validated signal

1012   A non-validated signal is a signal for which the signal validation process could not verify that the
1013   available data was of sufficient quality and substance to justify further investigation of the possibility of
1014   a causal association between the product(s)/substance(s) and the suspected adverse event(s) or
1015   where the events are considered adequately described in the product information (see section 2.3.1.2).

1016   Just as validation of a signal does not imply establishment of a causal association, nor does non-
1017   validation of a signal mean that a causal association has been ruled out.

1018   Furthermore, a non-validated signal should not be confused with a refuted signal (see also section
1019   2.5.1). A non-validated signal has not been assessed fully and the question of causality has not been
1020   considered, while a refuted signal is a validated signal, where further assessment found the evidence
1021   insufficient to support a causal association.

1022   Outcome and rationale behind non-validation of signals should also be documented in a sufficient
1023   manner to allow for inspection 17 i.e. the decision to non-validate a signal and why this conclusion was
1024   reached should be documented by the MAH and this documentation should be made available to
1025   inspectors.

1026   It should be emphasised that a previous non-validation of a signal does not imply that the signal
1027   should never be investigated again. Following non-validation, monitoring of the issue should usually
1028   return to routine pharmacovigilance practices although there may be situations where future
1029   monitoring can be prioritised lower e.g. if a causal association was determined to be biologically
1030   implausible. Thresholds for when the signal is considered detected again may be established on a case-
1031   by-case basis and would need to consider both latency until redetection, seriousness and severity of
1032   the event as well as the amount of new data available and trends in reporting.
1033   Future validation processes may or may not lead to validation of a previously non-validated signal and
1034   previous non-validation of a signal should not automatically determine the outcome of any future
1035   validation. However, prior knowledge from validations may be taken into account when prioritising
1036   signals for validation (see also sections 2.2.1.9 and 2.2.2).




       17 Article 17(6) of CIR (EU) 2021/1281


       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                              Page 40/79

第 41 页

1037   2.3.3. Signal prioritisation after signal validation

1038   All validated signals will need to go through a full assessment and subsequently be submitted to IRIS-
1039   VSM. In most cases, it will likely make sense to move directly from the validation phase to the
1040   assessment phase. However, where multiple validated signals exist for the same product, it may be
1041   necessary to prioritise which signals to assess first. The general principles, factors to consider and
1042   impact on future monitoring explained in section 2.2. may be applied after validation as needed. If
1043   assessment of a validated signal is deprioritised, the potential impact on safety should be carefully
1044   considered and documented with the validation together with the rationale for deprioritisation.

1045   2.4. Signal Assessment

1046   Signal assessment is the comprehensive process of examining all relevant sources of information with
1047   the aim of determining whether there is a need for action. In order to achieve this, signal assessment
1048   should focus on assessing the causal relationship between a VMP and the AEs of interest for a validated
1049   signal. Therefore, signal assessment focuses on establishing whether the validated signal is likely to
1050   reflect a new causal association or a new aspect of a known causal association with the VMP, as well as
1051   further characterising the risk in order to implement appropriate action, if necessary. This assessment
1052   is based on a cumulative review of all available information, including, but not limited to, case reports,
1053   scientific literature, pharmacological data, clinical information and epidemiological findings.

1054   Clinical judgement is central to signal assessment and requires expert evaluation of the potential
1055   biological mechanism, the clinical and environmental context of the signal and the consistency of
1056   reported events. Within this framework, review of individual case narratives in the context of a case
1057   series is essential, as narratives provide additional critical information that cannot be captured through
1058   coded data or quantitative analyses alone.

1059   The outcome of a signal assessment may ultimately lead to a recommendation for actions, such as
1060   enhanced monitoring, a need for further investigation or implementation of risk minimisation
1061   measures, including updates to the product information (see also sections 2.5 and 2.6).

1062   Signal evaluation should therefore be conducted using a structured and scientifically sound set of
1063   methods applied in a proportionate manner and adapted to the characteristics of the specific signal
1064   under assessment and the available data. These methods aim to support a consistent and transparent
1065   assessment of whether the validated signal represents a new risk or new aspect of a known causal
1066   association of the VMP.

1067   The key elements to consider during signal assessment are outlined below. The list is not exhaustive
1068   and additional methods may be applied where considered relevant.

1069




       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                             Page 41/79

第 42 页

1070

1071      Figure 5: Signal assessment

1072   2.4.1. Broader search for data

1073   One of the cornerstones of the signal evaluation phase is the conduct of a comprehensive and
1074   systematic search for evidence from all relevant sources, with the objective of ensuring that the safety
1075   topic under assessment is thoroughly explored and that all available evidence is taken into
1076   consideration and put into the correct context. Beyond the analysis of spontaneous reports and
1077   quantitative signal detection outputs, a broad search for additional data is essential to conclude on the
1078   outcome of the signal.

1079   The following section therefore outlines the key data sources that should be considered during signal
1080   assessment. Searching for further information through these sources helps ensure that conclusions are
1081   based on all the available evidence.

1082   2.4.1.1. Adverse event reports

1083   If the signal was not initially triggered by adverse event reports, a cumulative search for cases should
1084   be performed in relevant databases. These cases should be included for assessment of causality (see
1085   also section 2.4.2).

1086   However, even if the signal was triggered from AERs, it may be relevant to perform additional broader
1087   searches for data to ensure all relevant evidence is captured (see also section 2.1.2.1).

1088   It should be assessed whether conceptually related VeDDRA terms are reported, which may represent
1089   clinical sequelae, complications or different stages/descriptors of the same event. A predefined


       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                           Page 42/79

第 43 页

1090   grouping of VeDDRA terms can be applied to capture the full clinical spectrum and avoid
1091   double-counting and display both grouped and individual-term analyses (see examples 44-45).


            Examples

            44: Related terms reflecting organ-specific toxicity:
                  For a suspected hepatic adverse reaction, reports may include VeDDRA terms such as
                  elevated liver enzymes, jaundice, hepatic failure, hepatic necrosis or hepatic
                  encephalopathy. These terms may represent different clinical stages, severity levels or
                  sequelae of the same underlying hepatic injury and should therefore be considered together
                  using a predefined grouping, while still allowing presentation of individual term analyses.

            45: Related terms reflecting a recognised clinical syndrome:
                  For known syndromes, conceptually linked clinical signs should be assessed collectively. For
                  example, in a Limping-syndrome, reports of limping, pyrexia, lethargy and joint swelling
                  may be recorded under separate VeDDRA terms but represent manifestations of a single
                  clinical entity. Grouping such associated terms helps capture the full syndrome presentation
                  and avoids underestimation of the signal due to fragmented reporting.


1092   2.4.1.2. Experimental, non-clinical data and post-marketing surveillance studies

1093   Toxicology, pharmacokinetic (PK), pharmacodynamic (PD) and target organ data can provide evidence
1094   of a potential biological mechanism or identify susceptible organ systems or biochemical pathways.
1095   Data sources may be from the pre-authorisation phase of the product itself or new pre-clinical studies,
1096   or from scientific literature concerning the product, active substance(s) or similar substances published
1097   before or after authorisation of the product in the same or a different species (including humans).

1098   In addition, post-authorisation data generated under field conditions, including post-marketing
1099   surveillance studies (PMSS), may provide relevant complementary evidence. The definition of PMSS
1100   can be found in the VGVP module: Glossary 18.

1101   2.4.1.3. Clinical trial findings

1102   When pre- or post-authorisation clinical trial data exist, they can help characterise the adverse event
1103   regarding frequency, time-to-onset, dose administered and controlled-use conditions. Although
1104   veterinary clinical trials often have limited sample sizes, they may corroborate patterns seen in post-
1105   marketing pharmacovigilance.

1106   However, attention should be given to the fact that sample size of clinical trials affects the ability of the
1107   trial to detect very rare, rare and sometimes also uncommon events. Therefore, absence of an adverse
1108   event during clinical trials is not in itself sufficient reason to refute a signal but may point to the event
1109   occurring less commonly. Again, data sources may be from the pre-authorisation phase of the product
1110   itself or may be from scientific literature concerning the product, active substance(s) or similar
1111   substances published before or after authorisation of the product in the same or a different species
1112   (including humans).




       18 https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-veterinary-good-

       pharmacovigilance-practices-vgvp-module-glossary_en.pdf

       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                                  Page 43/79

第 44 页

1113   2.4.1.4. Other published literature (including data on similar substances or within the same
1114   product class)

1115   Scientific literature should be reviewed to identify evidence of the same or similar adverse events in
1116   the same species, in other species or in products that share the same active substance(s), excipients
1117   (if an excipient is suspected in the mechanism of the signal), mechanisms of action or pharmacological
1118   class. Exploring related VeDDRA terms can help capture different clinical manifestations or stages of
1119   the same pathophysiological process.

1120   2.4.1.5. Epidemiological data

1121   Information on the background prevalence of the reaction or disorder might provide contextual
1122   information to assess whether observed reporting incidences may exceed those expected. Background
1123   incidence may be available for the overall reference population or for relevant subpopulations (e.g.
1124   breed, underlying conditions, management practices).

1125   This factor may be particularly relevant for events with a long time-to-onset (e.g. neoplasia) or
1126   multifactorial aetiology (e.g. atopy, inflammatory bowel disease).

1127   However, important limitations must be considered. Comparisons between background incidence
1128   estimates and reporting incidences derived from spontaneous reports are inherently challenging due to
1129   underreporting, reporting biases and differences in study design and population definitions.
1130   Spontaneous reporting systems are not designed to estimate true incidence.

1131   Consequently, background incidence data should not be used in isolation to support or refute a causal
1132   association. Epidemiological information should be interpreted cautiously and qualitatively, in
1133   conjunction with other lines of evidence, including case-level data, biological plausibility and clinical
1134   pattern analysis (see examples 46-48).




       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                              Page 44/79

第 45 页

            Examples

            46: Long latency events with high background incidence

                  For adverse events that develop slowly and have a relatively high background incidence in
                  the target population, epidemiological context is essential to interpret a potential signal.
                  For example, a signal concerning mast cell tumours in dogs requires careful consideration of
                  background incidence, as mast cell tumours are among the most common cutaneous
                  neoplasms in this species and neoplastic processes typically have a long TTO. Knowledge of
                  the expected incidence in the general dog population is therefore important to assess
                  whether the number and pattern of reported cases following exposure to the product exceed
                  what would be anticipated by chance alone and to avoid false attribution of causality.

            47: Multifactorial diseases with fluctuating clinical course

                  Background incidence data are particularly informative for adverse events or conditions with
                  multifactorial aetiology and variable clinical expression, such as atopy, inflammatory bowel
                  disease or chronic renal disease. In these cases, episodic worsening may coincide temporally
                  with treatment initiation without being causally related. Population‑level data on expected
                  prevalence and incidence help contextualise observed reporting patterns and support
                  differentiation between disease progression and a treatment‑related effect.

            48: Situations where background incidence alone is insufficient

                  Abortions in sheep have a known background incidence and are commonly associated with
                  infectious, nutritional or management-related causes. The background incidence may vary
                  considerably depending on region, flock management practices and breed. When evaluating
                  a signal of abortion potentially associated with a VMP, the overall abortion rate observed in
                  exposed flocks may not exceed the expected background level. However, epidemiological
                  evaluation should consider whether exposure is associated with:
                  • Abortions occurring shortly after treatment (plausible and shortened TTO) and/or
                  • Temporal clustering of abortion cases following product administration.
                  In such situations, the product may not increase the overall incidence of abortion but may
                  act as a trigger, shifting the timing of events. Therefore, background incidence alone may be
                  insufficient to assess the clinical relevance of the signal.


1135   2.4.1.6. Information from other regulatory authorities worldwide

1136   Information originating from non-EU regulatory authorities may provide valuable complementary
1137   evidence during signal assessment. Signals detected, risk communications issued, or regulatory
1138   measures taken by authorities outside the EU can serve as indicators of potential risks or provide
1139   important contextual information, particularly when EU case data are limited or still emerging.

1140   Such information may include relevant pharmacovigilance data as well as regulatory measures adopted
1141   by competent authorities in third countries (e.g. restrictions of use, updates to product information,
1142   suspensions or withdrawals), particularly where these are not yet reflected in the EU product
1143   information and may have an impact on the benefit-risk balance.

1144   The information from these sources should be evaluated critically, taking into account differences in
1145   authorised indications, formulations, target species, patterns of use, reporting systems and regulatory
1146   frameworks. While actions taken by non-EU authorities do not automatically imply a causal association



       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                               Page 45/79

第 46 页

1147   under EU conditions of use, they may be supportive of the signal, or they may highlight potential class
1148   effects, or help identify subpopulations or conditions of use which may lead to increased risk.

1149   This information may be particularly relevant for serious, unexpected, or rare adverse events, for
1150   products or active substances used globally, or where similar safety concerns emerge independently
1151   across regions (see examples 49-50).


            Examples

            49: A safety communication issued by a non-EU authority warning of rare but serious
                  neurological adverse events associated with a specific pharmacological class may include
                  information in support of a similar signal detected in EU pharmacovigilance data.

            50: Regulatory restrictions or label changes implemented in another region following reports of
                  environmental harm linked to an antiparasitic product (e.g. effects on non-target
                  invertebrates) usually indicates that an analysis in that country has found a correlation.
                  Available information may be valuable for assessment of a similar signal in the EU. It may
                  also provide relevant context when assessing an environmental signal under EU conditions,
                  particularly where exposure patterns or use scenarios are comparable.


1152   2.4.2. Assessment of case series

1153   The completeness, clarity, internal consistency and reliability of each case are important determinants
1154   of the ability to assess causality. High quality, well-documented cases provide a more robust and
1155   reliable evidence base and are critical for drawing scientifically sound conclusions and determining the
1156   appropriate signal outcome.

1157




       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                             Page 46/79

第 47 页

1158

1159      Figure 6: Assessment of case series


1160   2.4.2.1. Case selection and search methodology

1161   For any analysis of case series conducted in the context of signal assessment, the methods used for
1162   case identification and selection should be clearly defined and transparently reported. This includes the
1163   databases searched, search strategies (e.g. terms or groupings applied), inclusion and exclusion
1164   criteria and any applied filters (e.g. seriousness, species, time period or level of documentation).

1165   Where focused analyses are conducted as part of the signal assessment (e.g. for a specific adverse
1166   event or signal of interest), it is essential that the approach to case selection is reproducible and
1167   sufficiently detailed to allow independent evaluation. Lack of clarity in case selection or search
1168   methodology may limit interpretability and introduce bias into the assessment.

1169   In situations where a complete review of all individual reports may not be feasible, selection criteria
1170   maybe useful to reduce the number of cases to be reviewed. The use of percentages may support
1171   interpretation, and the criteria should always be clearly stated.

1172   2.4.2.2. Key components of causality assessment at signal level

1173   The detailed review and assessment of adverse event reports (AERs), including case narratives, is a
1174   key component of signal assessment. This step aims to evaluate the potential causal association
1175   between exposure to a VMP and the AEs of interest, thereby contributing to the identification and
1176   characterisation of potential safety risks and supporting timely, proportionate regulatory
1177   decision-making.


       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                                Page 47/79

第 48 页

1178   The assessment of individual cases in the context of signal assessment should not be interpreted as a
1179   requirement to assign a formal causality category to all reported adverse event reports. A distinction
1180   should be made between assigning a formal overall causality assessment of an AER (which may involve
1181   multiple events and/or multiple products) and the targeted assessment of a defined case series
1182   addressing a specific event (or group of related events) included in the signal and its potential causal
1183   association with a specific product/substance. The purpose of the latter is to determine the extent to
1184   which the available cases support or weaken the product-event association under investigation.

1185   As most AERs are based on clinical suspicion, certainty regarding causality is rarely achievable and not
1186   required for decision making. The structured evaluation of individual cases should provide a
1187   transparent and reproducible framework to assess causal plausibility, distinguishing potentially
1188   product-related events from coincidental or background occurrences.

1189   This assessment also supports the prioritisation of signals for further benefit–risk evaluation and the
1190   consideration of appropriate risk minimisation measures, including potential updates to product
1191   information. Relevant contextual factors, such as co-reporting of lack of expected efficacy and use
1192   outside the terms of the marketing authorisation (off-label use), may also be considered.

1193   All relevant cases should be assessed using a consistent approach and, where appropriate, categorised
1194   according to the strength of evidence supporting a causal association. The total number of supportive
1195   cases should be determined and their strength as evidence of an overall causal association should be
1196   clearly evaluated.

1197   When assessing whether cases support a causal association, the following elements should be
1198   considered:

1199   Quality and completeness of case data

1200   Adverse event reports, including case narratives and structured data fields, should include sufficient
1201   detail to support evaluation of causality and clinical plausibility. In addition to the minimum criteria,
1202   ideally cases should include: a description/diagnosis of the AE, the temporal relationship to VMP
1203   exposure (which may be captured in structured fields such as time-to-onset), relevant animal
1204   characteristics and clinical background, co-reported treatments, outcomes and available follow-up. The
1205   information should also enable identification of potential confounders and alternative aetiologies.

1206   Review of case narratives remains essential to provide clinical context, risk characterisation and
1207   interpretative detail that may not be captured in coded or structured data. However, ideal cases are
1208   not the norm, and flexibility should be applied even when all desired information is not present.

1209   Cases with incomplete, unclear or inconsistent information limit interpretability and may introduce
1210   uncertainty or bias into the assessment. Such poorly documented cases should therefore be
1211   interpreted with caution and weighed accordingly in the overall evaluation, in conjunction with other
1212   lines of evidence.

1213   Where the overall information available from the entire case series is insufficient to assess causality or
1214   clinical plausibility, additional data or clarification should be sought whenever feasible, applying a
1215   risk‑based and proportionate approach. Where relevant, this may include the identification of specific
1216   information needed (e.g. additional diagnostic investigations or clinical details) to support improved
1217   assessment in future cases.

1218   Time-to-onset (TTO)

1219   It should be assessed whether the interval between exposure to the VMP and the onset of the adverse
1220   event is compatible with a biologically plausible mechanism of action. The expected TTO depends on
1221   the pharmacological properties of the product and the nature of the adverse event. Both very short

       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                              Page 48/79

第 49 页

1222   and delayed onsets may be plausible, provided they are consistent with the pharmacokinetics and
1223   pharmacodynamics of the product and/or known or hypothesised mechanisms, if available.

1224   A TTO that is poorly compatible with the expected pharmacology or pathophysiology may weaken the
1225   causal relationship for the case in question, whereas a consistent and reproducible TTO across cases
1226   can strengthen the signal. Characterising typical TTO over the entire case-series is also relevant for
1227   characterisation of the risk (see examples 51-53).


            Examples

            51: Compatible TTO (acute pharmacodynamic effect):
                  In horses treated with an α2‑agonist, profound sedation and bradycardia occurring within 5
                  minutes of administration is highly compatible with the known mechanism of action and
                  supports a signal of bradycardia.

            51: Compatible TTO (delayed toxicity):
                  In cats, elevations of Alanine aminotransferase (ALT) and Alkaline phosphatase (ALP)
                  occurring 3–4 weeks after initiation of an azole antifungal are compatible with subacute or
                  idiosyncratic hepatotoxicity.

            53: Non‑compatible TTO:
                  The occurrence of an adverse event on the same day as first administration for an event
                  known to require prolonged exposure (e.g. cataract formation, malignant neoplasia or
                  chronic organ damage), represents a time‑to‑onset that is not biologically plausible and
                  argues against a causal relationship.




1228


1229   Dechallenge

1230   A dechallenge refers to the withdrawal of a VMP, or in some cases a reduction in dose, following the
1231   occurrence of the adverse event of interest. Dechallenge may be undertaken intentionally to observe
1232   the effect of treatment withdrawal or may occur incidentally as part of routine clinical management.

1233   A dechallenge is considered positive when the adverse event or clinical signs improve after
1234   discontinuation or dose reduction. When assessing a dechallenge, it is important to consider potential
1235   confounding factors that may influence recovery, such as concurrent treatments, supportive care or
1236   the expected natural course and duration of the event. The time to improvement following withdrawal
1237   should also be evaluated to determine whether it is consistent with the elimination time of the product
1238   and expected end of clinical effect.

1239   A positive dechallenge is generally considered to significantly strengthen the causal association for any
1240   individual case and the presence of one or more cases with positive dechallenge(s) is considered
1241   supportive evidence in favour of the signal (see example 54).




       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                             Page 49/79

第 50 页

            Example

            54: A signal is identified in dogs presenting with intense pruritus during treatment with an
                  ectoparasiticide administered via a collar. Across several cases, a consistent pattern is
                  observed: pruritus develops shortly after collar application, in the absence of concurrent
                  medications or other identifiable triggers (e.g. no evidence of flea or other ectoparasite
                  infestation, allergic disease or environmental factors).
                  Following removal of the collar, clinical signs improve markedly within a few days without
                  additional therapeutic intervention. This clear temporal relationship between exposure (collar
                  application) and resolution of clinical signs upon withdrawal (collar removal) constitutes a
                  positive dechallenge. Considering the known pharmacological activity of the ectoparasiticide,
                  this observation supports a causal association between collar use and pruritus.



1242   Rechallenge

1243   A rechallenge occurs when a product or active substance is reintroduced, or the dose is increased,
1244   after a previous dechallenge. A rechallenge is considered positive if the adverse event reoccurs or
1245   worsens following re‑exposure.

1246   Reintroduction of treatment suspected to cause adverse events may be unethical or present
1247   unacceptable risk to the animal, particularly when the suspected adverse events are serious. When a
1248   rechallenge is available, the assessment should consider the same factors as for dechallenge, including
1249   timing of recurrence, consistency of clinical signs and potential alternative explanations.

1250   Cases with positive rechallenge are considered very strong evidence in favour of a causal association
1251   (see example 55).


            Example

            55: (Same dogs with pruritus from an ectoparasiticide from example 54): In a few of the cases
                  described in example 54, following complete resolution of pruritus after removal of the
                  ectoparasiticide collar (positive dechallenge), the same product is re‑applied at a later time.
                  Intense pruritus reappears shortly after re‑exposure, consistent with the previous clinical
                  presentation and in the absence of alternative explanations.
                  This recurrence of clinical signs upon re‑administration constitutes a positive rechallenge and
                  provides very strong support for a causal relationship between the ectoparasiticide collar and
                  the observed adverse reaction.



1252   Alternative causes

1253   When assessing a signal, it is essential to systematically evaluate whether the reported adverse event
1254   may be more likely explained by causes other than exposure to the VMP. Consideration of alternative
1255   explanations helps avoid false attribution of causality and supports a balanced, scientifically robust
1256   assessment.

1257   Potential alternative causes may include underlying or concurrent disease, infectious agents,
1258   management or husbandry factors, diagnostic or therapeutic procedures, environmental exposures or
1259   the natural course of the condition being treated.

1260   The assessment of alternative causes should take into account:


       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                              Page 50/79

第 51 页

1261       •     Clinical context: e.g. presence of pre-existing conditions, comorbidities, age-related
1262             susceptibility or disease progression that could reasonably explain the event fully or partially.

1263       •     Temporal relationships: Whether the timing of onset is more consistent with an alternative
1264             cause than with exposure to the product.

1265       •     Population patterns: e.g. occurrence of similar clinical signs in animals not exposed to the
1266             product, suggesting a background, management‑related or infectious origin.

1267       •     Procedures and environment: e.g. recent interventions (e.g. surgery, injection, transport),
1268             housing conditions, feed changes, environmental stressors or toxins.

1269   Alternative causes should be evaluated in the context of all available information and weighed against
1270   evidence supporting a product‑related effect (see examples 56-57).


            Examples

            56: Diarrhoea is reported in calves following administration of an antibiotic. However, PCR
                  testing confirms rotavirus infection and similar diarrhoeal clinical signs are observed in
                  multiple untreated calves on the same farm. The temporal and epidemiological pattern is
                  therefore more consistent with an infectious background cause than with a drug-related
                  adverse event, making a causal association with the product unlikely.

            57: An acute anaphylactic reaction is reported shortly after administration of multiple vaccines
                  during the same visit. The presence of more than one concurrently administered product
                  represents a relevant alternative explanation and prevents attribution of causality to a single
                  vaccine. Nevertheless, anaphylaxis is a well-defined, highly specific clinical syndrome with a
                  strong association with medicinal product exposure and few plausible non-drug causes. In
                  this context, the causal association with vaccination remains possible, even though
                  attribution to an individual product is not feasible.



1271   Co-reported treatments and potential drug–drug interactions

1272   The presence of co-reported treatments and their potential to contribute to, modify or fully explain the
1273   reported adverse event should be assessed. This assessment should include consideration of possible
1274   drug–drug interactions, including pharmacokinetic and pharmacodynamic interactions, additive or
1275   synergistic effects, as well as confounding by indication or by underlying disease requiring co-
1276   treatment.

1277   Particular attention should be paid to whether a co-reported medicinal product has a known association
1278   with the reported event, as documented in its product information or in the published literature and
1279   whether the time-to-onset is plausible and consistent with the reported event. In such situations,
1280   attribution of the event to the product under investigation may be weakened, especially when the
1281   alternative explanation offers a more plausible or well-established causal relationship (see examples
1282   58-60).




       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                               Page 51/79

第 52 页

            Examples

            58: Drug–drug interaction (additive or synergistic effects)

                  Bradycardia is observed during sedation in a dog receiving an α2-adrenergic agonist in
                  combination with acepromazine and an opioid. All administered products are known to exert
                  cardiovascular depressant effects, and the timing and clinical presentation are consistent
                  with an additive or synergistic pharmacodynamic interaction. Unless overdose of a specific
                  product is identified, the event is more plausibly explained by combined drug effects rather
                  than by a single causal agent.

            59: Concurrent treatment as the more likely culprit

                  A signal of gastrointestinal ulceration is reported in dogs receiving long-term phenobarbital
                  therapy. However, review of case narratives identifies recent concurrent administration of a
                  non-steroidal anti-inflammatory drug (NSAID) in the period immediately preceding onset of
                  clinical signs. NSAIDs are well recognised to be associated with gastrointestinal ulceration
                  and bleeding, with a plausible TTO, whereas phenobarbital is not commonly linked to this
                  adverse event. In this context, the concurrent NSAID represents a more plausible causal
                  explanation, weakening attribution to phenobarbital.

            60: Equal plausibility of concurrent treatments

                  A dog receives an NSAID and an antibiotic concurrently and subsequently develops
                  diarrhoea and anorexia. Both medicinal products are known to be associated with
                  gastrointestinal adverse events and the TTO is compatible with exposure to either treatment.
                  In the absence of dechallenge or other distinguishing clinical features, both products
                  represent plausible contributors and attribution of causality to a single product is not
                  possible. The causal association with each product should therefore be considered possible.



1283   Adverse events specifically known to be drug-related

1284   Assess whether the reported adverse event represents a highly specific clinical syndrome or a
1285   well‑defined medical condition that is known to be strongly associated with drug exposure and has a
1286   limited number of alternative causes. Adverse events with a characteristic and recognisable clinical
1287   presentation may have a high predictive value for a drug‑related effect and can therefore strongly
1288   support causality, even in the absence of multiple cases.

1289   This criterion focuses on the nature and specificity of the event itself, rather than on its frequency or
1290   TTO. Events that are considered medically significant conditions often fall into this category due to
1291   their seriousness and strong association with medicinal products.

1292   Examples of specific syndromes known to be drug-related include immediate anaphylaxis, toxic
1293   epidermal necrolysis, agranulocytosis or acute hepatic failure, where alternative explanations are
1294   limited and a drug-related mechanism is well recognised (see also example 61).




       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                                 Page 52/79

第 53 页

            Example

            61: A cat develops a progressive, locally invasive fibrosarcoma at a previous injection site.
                  Injection-site sarcoma in cats is a well-recognised, specific pathological entity strongly
                  associated with prior parenteral administration of VMPs, particularly vaccines or other
                  injectable substances. Although TTO may be prolonged, the characteristic tumour type,
                  anatomical localisation and clinical progression form a highly specific clinical picture with
                  limited alternative explanations. The specificity of this malignancy therefore provides strong
                  support for a causal association with previous injection exposure, even in the absence of
                  clustering in time or multiple comparable cases.



1295   Consistency across cases

1296   Assess whether similar patterns are observed across multiple cases, including consistency in TTO,
1297   clinical presentation, severity, outcome or affected subpopulations. Reproducible patterns strengthen
1298   the signal and support a causal association, particularly when they are observed independently and are
1299   not readily explained by alternative causes.

1300   Use of predefined VeDDRA groupings is recommended to capture the full clinical spectrum of an event,
1301   including related clinical signs, stages or manifestations and to avoid fragmentation or double counting
1302   of conceptually linked terms (see example 62).


            Example

            62: A series of reports describes dogs developing urticaria followed by facial oedema within 30
                  minutes of injection. Similar time-to-onset and clinical progression are observed across
                  cases, with small breeds disproportionately represented. The consistency of clinical features,
                  timing and affected subpopulation supports a coherent hypersensitivity signal.



1303   Dose-response relationship (if applicable)

1304   Assess whether there appears to be a relationship between dose, duration of exposure, or cumulative
1305   exposure and the occurrence, severity or duration of the adverse event. The key question to address is
1306   whether higher doses, longer treatment duration or use outside the authorised conditions are
1307   associated with an increased likelihood, earlier onset or greater severity of the event. Identification of
1308   such patterns may support pharmacological plausibility and strengthen the causal assessment.

1309   However, it is important to recognise that not all adverse events are dose dependent. Idiosyncratic
1310   reactions, immunologically mediated events or hypersensitivity reactions may occur independently of
1311   dose or exposure duration. Therefore, absence of a clear dose–response relationship does not exclude
1312   a causal association and should be interpreted in the context of the known pharmacology of the
1313   product and the nature of the event (see examples 63-65).




       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                               Page 53/79

第 54 页

              Examples

              63: A cat develops polyuria/polydipsia and elevated liver enzymes following administration of a
                  high dose of a corticosteroid over a prolonged period. The severity and persistence of clinical
                  signs increase with continued exposure, consistent with a dose and duration dependent
                  adverse event and supporting a causal relationship.

              64: A cat tolerates long-term treatment with low-dose corticosteroids without adverse events.
                  Following an increase in dose due to disease flare-up, the cat develops clinical signs
                  consistent with iatrogenic Cushing’s syndrome. Across several cases, more severe clinical
                  signs are observed in animals receiving higher doses compared with those treated at lower
                  doses, supporting a dose-dependent relationship.

              65: Several dogs develop acute hypersensitivity reactions following administration of an
                  ectoparasiticide. The reactions are reported after standard authorised doses and there is no
                  evidence that higher doses increase either the frequency or severity of the reactions. As
                  hypersensitivity reactions are typically immune-mediated and not dose-dependent, the
                  absence of a dose–response relationship does not argue against a causal association.


1314   2.4.2.3. Standardised systems for causality assessment

1315   All case reports included in signal evaluation should be categorised for causality using consistent and
1316   predefined categories and supported by a clear and explicit rationale. The assessment should
1317   document the applied criteria as well as the key elements supporting or arguing against a causal
1318   association, such as temporal relationship, dechallenge/rechallenge, biological plausibility and the
1319   presence of alternative causes.

1320   Use of standardised causality assessment systems ensures transparent, reproducible and harmonised
1321   evaluations, facilitates prioritisation of signals for further follow‑up and supports proportionate and
1322   consistent benefit–risk decision‑making at both MAH and regulatory authority level.

1323   Although standardised systems can support these objectives, there is no longer a regulatory
1324   requirement in the EU to assign a formal overall causality category to each adverse event report.
1325   Nevertheless, a structured and transparent evaluation of causal plausibility remains essential for the
1326   identification and selection of cases supporting a signal, as well as for the overall signal assessment.

1327   This approach reflects the distinction between assigning an overall causality classification to a single
1328   case and evaluating the causal plausibility of a specific medicinal product–event association across a
1329   series of cases within the context of signal management.

1330   Several causality assessment systems and criteria have been described in pharmacovigilance,
1331   however, the only system specifically adapted for veterinary pharmacovigilance is the ABON system,
1332   which is widely used and accepted within the EU veterinary regulatory framework (see examples 66-
1333   69).

1334




       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                               Page 54/79

第 55 页

     Examples

     66: ABON System

           The ABON system provides a structured approach to classify the likelihood of a causal
           association between a VMP and a reported adverse event. It is specifically adapted for use in
           veterinary pharmacovigilance and supports consistent and transparent assessment of
           individual cases.

           The ABON causality categories are defined as follows:

           A – Probable: A reasonable temporal relationship to product administration is present; the
           event is consistent with known pharmacological or biological properties of the product;
           alternative causes are unlikely; and, where available, dechallenge information is supportive.

           B – Possible: A temporal relationship exists; however, alternative explanations such as
           underlying disease or concurrent treatments cannot be excluded.

           O1 – Insufficiently documented (assessment pending): A causal association cannot be
           assessed because key information is missing or still under investigation. Additional data may
           reasonably be expected to allow further evaluation.

           O – Unclassifiable / insufficient data: Available information is inadequate, contradictory or
           incomplete, preventing meaningful assessment and no further data are expected to become
           available.

           N – Unlikely: The event shows no reasonable temporal relationship to product administration
           or is more plausibly explained by alternative causes.

           The ABON system is based on evaluation of six core factors:

           1.        Temporal relationship between exposure and event

           2.        Pharmacological or biological plausibility

           3.        Clinical and/or pathological findings

           4.        Prior knowledge, including published literature and product information

           5.        Consideration of alternative causes

           6.        Quality and reliability of the available data

           By systematically applying these criteria, the ABON system supports harmonised
           interpretation of individual cases and provides a common framework and terminology for
           causality assessment in veterinary pharmacovigilance.


     Several systems, optimised for use in human pharmacovigilance also exist, for example:

     67: WHO–UMC Causality Assessment System

           The WHO–UMC system classifies the likelihood of a causal association using standardised
           categories (Certain, Probable/Likely, Possible, Unlikely, Conditional/Unclassified,
           Unassessable).

     68: Naranjo Algorithm



Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
Management
EMA/522332/2021 Rev.1                                                                              Page 55/79

第 56 页

                  The Naranjo algorithm is a questionnaire-based scoring system designed to provide a
                  structured estimate of causality (Definite, Probable, Possible, Doubtful) based on factors
                  such as temporal relationship, dechallenge/rechallenge, alternative causes and prior
                  knowledge.

            69: Bradford Hill Criteria

                  The Bradford Hill criteria describe a set of general epidemiological considerations (e.g.
                  strength and consistency of association, temporality, biological gradient, plausibility and
                  coherence) to support inference of causality between an exposure and an outcome.

             References:

             https://www.who.int/docs/default-source/medicines/pharmacovigilance/whocausality-
            assessment.pdf

             Naranjo CA et al. A method for estimating the probability of adverse drug reactions.
            Clin Pharmacol Ther. Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi:
            10.1038/clpt.1981.154.

             Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965
            May;58(5):295–300. doi: 10.1177/003591576505800503



1335   2.4.3. Investigation of biological mechanism

1336   The investigation of a biological mechanism is a critical component in the assessment of a
1337   pharmacovigilance signal. It aims to determine whether there is a scientifically plausible explanation
1338   for the potential causal relationship between the suspected adverse event and the VMP. Establishing
1339   such a mechanism strengthens the case for a causal association and supports regulatory decision-
1340   making.

1341   A structured assessment of biological plausibility typically begins with the key question:

1342       •    Is there a reasonable biological mechanism that could explain the adverse event?

1343   If the answer is yes, this biological rationale reinforces the signal, increases its credibility and may
1344   guide further actions (e.g. targeted data collection, risk minimisation measures).

1345   If no plausible mechanism is identified, it is crucial to distinguish between a genuine absence of
1346   biological plausibility, suggesting that a causal association is unlikely, or insufficient data or incomplete
1347   scientific understanding, meaning that the lack of a mechanism should not be interpreted as disproving
1348   the association.

1349   Elements to consider when investigating whether there is a potential biological mechanism are
1350   summarised in this section. The list should not be considered exhaustive.

1351   2.4.3.1. Pharmacodynamics (PD)

1352   It should be evaluated whether the intended mode of action or secondary pharmacological effects of
1353   the product could logically lead to the observed event (see example 70).




       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                               Page 56/79

第 57 页

            Example

            70: A prostaglandin analogue used for oestrus synchronisation is known to also cause smooth
                  muscle contraction. Contraction of smooth muscle in airways would be a plausible
                  mechanism for an adverse event such as broncho-constriction in susceptible animals.


1354   2.4.3.2. Pharmacokinetics (PK)

1355   The following aspects should be considered: systemic exposure, absorption, distribution, metabolism
1356   and excretion of the product, including the formation of active or toxic metabolites, potential
1357   accumulation with repeated dosing and pharmacokinetic interactions with concurrent treatments (see
1358   examples 71-73).


            Examples

            71: A product that is predominantly excreted via the kidneys, either unchanged or as
                  metabolites, may be more plausibly associated with renal adverse events than a product
                  primarily cleared through hepatic metabolism and biliary excretion. Such considerations are
                  particularly relevant when evaluating signals related to renal toxicity, changes in renal
                  function parameters or exacerbation of pre‑existing renal disease.

            72: A signal of hepatic encephalopathy is identified for a VMP that is extensively metabolised in
                  the liver and cases appear to occur primarily in treated animals with pre-existing hepatic
                  disease. Impaired hepatic metabolism and clearance may result in accumulation of the
                  parent compound or active metabolites, leading to increased systemic exposure and
                  neurological signs. Therefore, the pharmacokinetic reliance on hepatic function supports a
                  plausible mechanism for the observed adverse events.

            73: A drug known to cross the blood-brain barrier (in all or certain individuals) is more likely to
                  cause seizures or other neurological AEs.


1359   2.4.3.3. Toxicology and Non-Clinical Findings

1360   Prior or newly identified knowledge from non-clinical studies, including toxicology, safety pharmacology
1361   and target-organ findings, should be considered when investigating the potential biological mechanism
1362   behind a signal. Such data may originate from the product itself, related substances, or experience in
1363   other animal species or in humans and can provide important insight into relevant biochemical
1364   pathways or susceptible organs (see example 74).


            Example

            74: Mild liver enzyme elevations observed in repeat‑dose toxicology studies in dogs, or evidence
                  of hepatotoxicity reported in another species or in humans, can support the plausibility of
                  hepatobiliary adverse events reported post‑authorisation in the target species.


1365   2.4.3.4. Specific susceptibility of subpopulations

1366   Certain subpopulations may present specific physiological, genetic or pathological characteristics that
1367   increase their vulnerability to adverse events. Such susceptibilities may be related to species-specific
1368   or breed-specific traits, explicit genetic factors (e.g. polymorphisms affecting metabolism or target

       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                              Page 57/79

第 58 页

1369   receptors), age, reproductive status, or the presence of underlying diseases or concurrent conditions.
1370   Identification of these factors can support biological plausibility and help refine the risk characterisation
1371   of a signal. Where a susceptible subpopulation is identified and considered clinically relevant, this
1372   information may contribute to subsequent risk minimisation measures or amendments to the product
1373   information (see examples 75-78).


            Examples

            75: Genetic or breed-related susceptibility:
                  Dogs of collie-type breeds carrying the MDR1 gene mutation have increased susceptibility to
                  ivermectin-induced neurotoxicity due to impaired P-glycoprotein function at the blood–brain
                  barrier.

            76: Comorbidity-related susceptibility:
                  Epileptic dogs may be more susceptible to seizures when exposed to medicinal products with
                  the potential to lower the seizure threshold, such as certain ectoparasiticides.

            77: Age-related susceptibility:
                  Very young puppies, with immature hepatic metabolic capacity, may be at increased risk of
                  adverse effects when treated with non-steroidal anti-inflammatory drugs (NSAIDs).

            78: Species-specific sensitivity:
                  Cattle exhibit markedly higher sensitivity to alpha-2 adrenergic agonists compared to dogs,
                  resulting in a greater risk of overdose and pronounced pharmacodynamic effects at relatively
                  low doses.


1374   2.4.3.5. Literature and Post-Marketing Experience

1375   Published scientific literature and accumulated post‑marketing experience should be considered
1376   specifically to support the assessment of biological plausibility of a signal. This includes relevant
1377   evidence from case reports, mechanistic or pharmacological studies and clinical or field observations
1378   that help interpret the observed association.

1379   Particular attention should be given to evidence of known class effects, experience with the same
1380   active substance or information reflected in the product information of currently authorised products.
1381   Such data can provide important mechanistic context or indicate consistent patterns of adverse events,
1382   even when the precise underlying mechanism is not fully established (see example 79).


            Example

            79: If adverse gastrointestinal events are well recognised for other VMPs containing the same
                  active substance, or for products belonging to the same pharmacological class, this supports
                  the plausibility of a substance or class‑related mechanism.


1383   2.4.4. Special types of signals

1384   Some signals require specific consideration during assessment of causality due to their nature or
1385   inherent characteristic. These include signals related to lack of efficacy, medication errors, user safety,
1386   residues and public health and environmental risks. While the general principles of signal management
1387   apply, the assessment approach may need to be tailored to adequately address the specific risks
1388   involved and their broader implications.

       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                              Page 58/79

第 59 页

1389   2.4.4.1. Signals concerning lack of efficacy and antimicrobial resistance

1390   Signals of lack of expected efficacy (LEE) may arise from individual reports of treatment failure or from
1391   emerging patterns across multiple cases. Assessment should distinguish between issues related to
1392   conditions of use (e.g. incorrect dosing, non‑compliance, inappropriate indication, management
1393   factors) and those potentially reflecting reduced effectiveness of the product.

1394   Causality assessment should focus on whether the reported lack of effect is reasonable in light of the
1395   authorised indication(s). For products with multiple indications (e.g. treatment of different conditions
1396   or both clinical and microbiological claims), consistency across reports regarding the disputed
1397   indication should be examined.

1398   In the context of antimicrobials and antiparasitics, LEE signals may be indicative of emerging
1399   resistance, including antimicrobial resistance (AMR). Evaluation should consider evidence of reduced
1400   susceptibility of target organisms, regional or species-specific patterns and consistency with known or
1401   plausible resistance mechanisms.

1402   For vaccines, LEE signals may also reflect the emergence or spread of new or variant strains against
1403   which the currently authorised vaccine provides insufficient cross‑protection. In such cases, the
1404   assessment should consider the antigenic match, epidemiological trends and available evidence on
1405   circulating strains, as well as the precise indication of the VMP and statements in the PI regarding
1406   demonstrated cross‑protection against other or specific strains.

1407   Such signals may warrant closer monitoring, further investigation and coordination with resistance
1408   surveillance systems, antimicrobial stewardship activities and, where relevant, epidemiological and
1409   vaccine strain monitoring programmes.

1410   2.4.4.2. Signals concerning medication errors

1411   Signals related to medication errors may involve incorrect dosing, wrong route or species, misuse,
1412   accidental exposure of target or non‑target species, or issues related to product presentation, labelling
1413   or administration devices.

1414   Assessment should focus on identifying:

1415       •    The type and frequency of the error;

1416       •    Whether a pattern or recurrent cause can be identified;

1417       •    Whether the error is reasonably foreseeable and preventable;

1418       •    The potential consequences for animal health, user safety, public health or the environment.

1419   Medication errors may be considered preventable when they are reasonably foreseeable and linked to
1420   product design, labelling, instructions for use or real‑world use conditions.

1421   In cases of intentional misuse, the assessment should focus on the extent of occurrence, preventability
1422   and, where identifiable, the underlying reasons for the misuse (see also Guidance notes on the use of
1423   VeDDRA terminology for reporting suspected adverse events in humans and animals).

1424   2.4.4.3. Signals concerning user safety

1425   Signals affecting the people who are handling and administering the VMP, i.e. users (e.g. veterinarians,
1426   farmers, animal owners) require particular attention. All VeDDRA terms are considered medically
1427   important for humans.



       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                             Page 59/79

第 60 页

1428   The focus of the assessment is often similar to an assessment of medication errors, where focus is
1429   placed on identifying patterns leading up to the risk and the potential preventability of the risk and
1430   available treatment options.

1431   For example, needlestick injuries associated with mineral oil adjuvanted vaccines can result in severe
1432   human tissue injury and long-term morbidity. Such signals may warrant strong warnings in product
1433   information, enhanced training, changes in handling recommendations or implementation of safer
1434   administration practices.

1435   2.4.4.4. Signals concerning Residues/Public health

1436   Signals related to residues in food producing animals may indicate potential issues with withdrawal
1437   periods, compliance with authorised use conditions or residue depletion assumptions. Evaluation
1438   should consider whether reported findings suggest that existing withdrawal periods may be insufficient
1439   under certain conditions of use, animal categories or management practices.

1440   Such signals are of particular importance due to their potential implications for consumer safety and
1441   may require targeted investigations, review of residue data or regulatory action to protect public
1442   health.

1443   2.4.4.5. Signals concerning environmental risks

1444   Environmental signals relate to unintended adverse effects on non-target organisms or ecosystems
1445   following use of VMPs (see also sections 2.2.1.11 and 2.3.1.3). These may include, for example,
1446   adverse effects on dung fauna or water-environments associated with certain antiparasitic products.

1447   Assessment should focus on analysis of plausible routes of environmental exposure, assessment of
1448   preventability and consistency with known ecotoxicological properties of the active substance and
1449   potential real-world consequences for the environment. Where appropriate, the need for risk‑mitigation
1450   measures or restrictions of use should be considered.

1451   2.4.5. Risk characterisation

1452   Risk characterisation aims to describe the risk clearly and comprehensively, based on the totality of
1453   available evidence, in order to support benefit–risk evaluation and regulatory decision‑making. It
1454   focuses on defining the nature, seriousness, severity and frequency of the event(s).

1455   The outcome of the risk characterisation should clearly describe:

1456       •     What the risk is, including its clinical definition, seriousness and medical importance, as well as
1457             the observed range of severity and associated uncertainty;

1458       •     Who is at risk, taking into account species, breed, genotype, age, physiological status and
1459             relevant comorbidities;

1460       •     When and under which conditions it occurs, including time-to-onset, on‑label or off‑label use,
1461             route of administration, dose and conditions of use;

1462       •     How often the event occurs, where feasible.

1463   2.4.5.1. Defining the risk precisely

1464   In order to define the risk more precisely, the collective experience of the event(s) from all available
1465   sources should be summarised. The summary should clearly describe what occurred and in which
1466   animals, humans or environmental compartments.

       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                               Page 60/79

第 61 页

1467   Where available, the summary should include:

1468       •    Average time-to-onset, preferably together with the observed range (from–to) and/or
1469            distribution of time-to-onset should be reported where available, to capture variability and
1470            support a more precise characterisation of the temporal pattern of the event;

1471       •    Clinical course;

1472       •    Reversibility of the event(s), including the outcome of any dechallenge;

1473       •    Overall final outcome (recovered, recovered with sequelae, not recovered/outcome unknown,
1474            fatal);

1475       •    Any reported long‑term sequelae.

1476   Based on this summary, consideration should be given to identifying the VeDDRA term(s) that most
1477   precisely describe the event(s).

1478   An assessment of overall seriousness, severity and medical importance should then be performed. This
1479   includes classification of whether the event(s) meet seriousness criteria (e.g. death, life-threatening,
1480   significant disability, congenital anomaly or other medically important events), in accordance with
1481   internationally harmonised definitions (VICH GL24) (see also section 2.2.1.4). The range of severity,
1482   from mild to severe and where possible the proportion of severe cases among all assessed cases
1483   should also be characterised. The list of medically important terms may also be used at the step of
1484   signal assessment to assist the assessment of medical importance.

1485   Following causality assessment, the number and/or percentage of supportive cases should be known. A
1486   reporting incidence may be provided, calculated from the cumulative number of spontaneous reports
1487   and the estimated cumulative exposure. Reporting incidence is subject to limitations, including under-
1488   reporting, case ascertainment bias, stimulated reporting and uncertainty in exposure denominators.
1489   Therefore, other data sources, such as clinical trials or post-marketing surveillance studies, should be
1490   considered where available. Reporting incidence may contribute to signal characterisation but is neither
1491   supportive nor dismissive of a signal in itself.

1492   See examples 80-82 on how to summarise information.




       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                            Page 61/79

第 62 页

            Examples

            80: Based on EVVet data, the MAH safety database and literature, 18 cases of acute reactions
                  were identified in adult cattle following administration of an inactivated vaccine. Clinical
                  signs typically occurred within 5–30 minutes and included dyspnoea, collapse and
                  convulsions. Most affected animals improved following appropriate symptomatic treatment
                  and recovered completely. The final outcome was recovery in 13 animals and death in 5; no
                  long-term sequelae were reported. The most appropriate VeDDRA terms were Anaphylactic
                  reaction and Acute hypersensitivity. The events met VICH GL24 seriousness criteria (life-
                  threatening and fatal), with approximately 30% of cases classified as severe. Following
                  causality assessment, 14 cases were considered supportive. A reporting incidence was
                  estimated and interpreted with caution.

            81: A total of 245 spontaneous reports described vomiting and diarrhoea in dogs treated with an
                  NSAID at authorised doses. The average time‑to‑onset was 2–5 days after treatment
                  initiation. Clinical signs were generally mild and reversible, resolving shortly after treatment
                  discontinuation. Most animals recovered fully and no long‑term sequelae were reported. The
                  VeDDRA terms Vomiting and Diarrhoea were considered most appropriate. The events did
                  not meet seriousness criteria and severity was predominantly mild to moderate, with a low
                  proportion of severe cases. Following causality assessment, 180 cases were considered
                  supportive. A reporting incidence was calculated as a descriptive element of signal
                  characterisation.

            82: Thirty‑two reports described injection‑site reactions in cats following administration of a
                  long‑acting injectable product. The average time‑to‑onset was 7–21 days. The clinical course
                  included local swelling and, in some cases, abscess formation. Reversibility was variable and
                  surgical intervention was required in several cases. Most animals recovered, although
                  persistent local masses were reported as long‑term sequelae. The most relevant VeDDRA
                  terms were Injection site reaction and Injection site mass. While most events were
                  non‑serious, some were considered medically important. Following causality assessment, 20
                  cases were considered supportive and a reporting incidence was provided with the usual
                  limitations.



1493   Frequency estimates

1494   Following causality assessment, the number and/or percentage of supportive cases should be known.
1495   Where feasible, an estimate of event frequency may be provided to support signal characterisation.
1496   Frequency may be estimated either from the number of supportive cases identified through causality
1497   assessment or as a reporting incidence calculated from the cumulative number of spontaneous reports
1498   in relation to the estimated cumulative exposure (see Guideline on the calculation of dose factor to be
1499   submitted to the Union Product Database (UPD)41).

1500   Reporting incidence and other frequency estimates are subject to important limitations inherent to
1501   spontaneous reporting systems, including under‑reporting, reporting bias (including stimulated
1502   reporting following communications or media attention), case ascertainment bias and uncertainty in
1503   exposure denominators. Frequency estimates should therefore be interpreted with caution and
1504   considered hypothesis‑generating only. Where available, additional data sources, such as clinical trials,
1505   post‑authorisation surveillance or epidemiological studies, should be taken into account to support
1506   interpretation. Estimates should be reviewed as more robust data become available.



       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                               Page 62/79

第 63 页

1507   Irrespective of the method used, frequency estimates cannot be used to conclude on the likelihood of a
1508   causal association. They represent one element of risk characterisation and may become relevant
1509   where the outcome of the signal assessment is an update of the product information (see example 83).


            Example

            83: There were forty cases reported cumulatively. Twenty‑five of these were considered
                  supportive following causality assessment. Frequency may be estimated from the 25
                  supportive cases alone, or a reporting incidence may be calculated from the total number of
                  40 reported cases.
                  Based on estimated cumulative exposure, the reporting incidence suggests that the
                  frequency is rare while the frequency estimate from supportive cases alone suggests that
                  the event is very rare. However, given the likelihood of under‑reporting and uncertainty in
                  exposure estimates, estimates should be interpreted cautiously and used primarily to
                  support signal characterisation rather than to quantify true incidence. If one of the two
                  frequencies are to be used for a future product information update, the worst-case-scenario
                  is generally preferable.


1510   2.4.5.2. Identifying special circumstances of the risk

1511   The risk characterisation should identify and describe any special circumstances under which the risk is
1512   more likely to occur or may be exacerbated. These circumstances may relate to specific
1513   subpopulations, conditions of use, or product-related factors and are critical for refining risk awareness
1514   and informing appropriate risk minimisation measures. Additionally, any circumstances identified which
1515   reduce the risk of the event(s) either with respect to occurrence or outcome, should also be described.

1516   Restriction to specific subpopulations

1517   Certain risks may be confined to, or more pronounced in, particular subgroups due to physiological,
1518   genetic or pathological characteristics. These may include:

1519       •    Species, breeds or genotypes: For example, dogs of herding breeds carrying the MDR1
1520            (ABCB1) gene mutation are predisposed to neurotoxicity when exposed to certain macrocyclic
1521            lactones or loperamide, necessitating tailored warnings, dose restrictions or avoidance at
1522            higher doses.

1523       •    Age or physiological status: Increased susceptibility may be observed in neonates, geriatric
1524            animals, pregnant or lactating animals, or specific production classes (e.g. high-yield dairy
1525            cattle).

1526       •    Comorbidities and concurrent medication: Underlying renal or hepatic impairment,
1527            dehydration, or the use of interacting medicinal products (e.g. concurrent NSAIDs and
1528            corticosteroids) may increase the likelihood or severity of adverse outcomes.

1529   Conditions of use

1530   The circumstances under which a product is used may significantly influence the risk profile and should
1531   therefore be carefully evaluated. Relevant factors may include:

1532       •    Use outside authorised conditions: Off-label use, overdose, incorrect route or frequency of
1533            administration, misuse, medication errors, or issues related to product quality or specific
1534            batches.



       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                             Page 63/79

第 64 页

1535       •    Environmental or management factors: external conditions such as temperature extremes,
1536            transport or handling stress, housing conditions or, in aquaculture, water quality parameters,
1537            which may contribute to or exacerbate adverse effects.

1538   Product and formulation-related factors

1539   Specific characteristics of the product or its formulation may influence the occurrence or nature of the
1540   risk, including:

1541       •    Formulation and excipients: Certain excipients, solvents or adjuvants may contribute to
1542            hypersensitivity reactions or exacerbate toxicity.

1543       •    Presentation and delivery devices: Issues related to applicators, syringes or other delivery
1544            systems may facilitate incorrect dosing, misuse or accidental exposure.

1545   See examples 84-86.


            Examples

            84: Genotype-restricted neurotoxicity (macrocyclic lactones/loperamide in MDR1-mutant dogs):
                  Use of certain macrocyclic lactones or loperamide is associated with acute neurological
                  adverse events (e.g. ataxia, tremors, seizures) in dogs carrying the MDR1 (ABCB1) gene
                  mutation, predominantly affecting herding breeds. Events may be severe but are uncommon
                  and mainly reported following off-label or high-dose use or in the presence of interacting
                  co-medications. When products are used according to authorised conditions and
                  breed-specific precautions are followed, the likelihood of occurrence is low. Risk minimisation
                  includes strengthened SPC/PL warnings, avoidance or dose adjustment in susceptible breeds
                  and targeted monitoring.

            85: Several reports described increased incidence and severity of adverse cardiovascular and
                  respiratory events in pigs treated with a sedative during periods of high ambient
                  temperature. Most cases occurred during summer months and were associated with
                  treatment administered shortly before transport under conditions of heat and handling
                  stress. Clinical signs included hyperthermia, respiratory distress and collapse, with rapid
                  onset after administration. When the same product was used under comparable conditions
                  but at moderate temperatures and without transport‑related stress, adverse events were
                  infrequently reported and generally non‑serious. This suggests that high environmental
                  temperature combined with handling stress may exacerbate the risk and severity of adverse
                  outcomes.

            86: Several reports described increased acute gill irritation and respiratory distress in salmon
                  following bath treatment with an antiparasitic medicinal product formulated as a
                  concentrated aqueous solution. Clinical signs occurred during or shortly after exposure and
                  included increased opercular movement, surfacing behaviour and, in some cases, mortality.
                  The events were more frequently reported when the product was used at the upper end of
                  the authorised concentration range and in sea water with elevated salinity. Comparable
                  adverse events were rarely reported for alternative formulations of the same active
                  substance administered via in‑feed treatment. This pattern suggests that formulation‑related
                  characteristics affecting local exposure at the gill level, in combination with water
                  parameters, may exacerbate the risk.




       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                              Page 64/79

第 65 页

1546

1547      Figure 7: Risk characterisation checklist

1548   2.4.6. Overall conclusion

1549   The overall conclusion of a signal assessment should be comprised of both a risk statement and an
1550   overall evaluation of the causal association.

1551   Risk statement

1552   The outcome of risk characterisation should be summarised in a clear and concise risk statement that
1553   captures the key elements necessary to support regulatory decision‑making and risk communication.
1554   The risk statement should explicitly address:

1555       •    Nature of the risk: A precise clinical description of the adverse event, including seriousness and
1556            medical importance and an assessment of how frequently it occurs and how severe it appears
1557            to be acknowledging any uncertainty associated with the available data.

1558       •    Population at risk: Identification of the animal, user or environmental subpopulations at
1559            increased risk, including relevant species, breeds, genotypes, age groups, physiological states
1560            or comorbidities.

1561       •    Circumstances of occurrence: Description of when and under which conditions the risk occurs,
1562            including authorised versus off‑label use, route of administration, dose or duration of treatment
1563            and relevant environmental or management factors.


       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                             Page 65/79

第 66 页

1564       •    Broader implications: Consideration of potential implications for user safety, public health or
1565            the environment, where applicable.

1566       •    Likelihood under normal conditions of use: An overall assessment of the likelihood of the risk
1567            occurring when the product is used in accordance with the authorised conditions.

1568       •    Consequences and preventability of the risk: Outcome and consequences of the risk, including
1569            any identified circumstances which may reduce the risk (occurrence or severity), or ways to
1570            treat the consequences.

1571   Causality statement

1572   The overall conclusion on causality should be derived from a structured and balanced assessment of
1573   the likelihood of a causal association between the VMP and the reported adverse event(s), integrating
1574   the key findings from signal assessment and characterisation and reflecting the weight of the available
1575   evidence.

1576   The conclusion should summarise the strength of evidence supporting or refuting the signal, including
1577   biological and pharmacological plausibility and the principal causality elements considered (e.g.
1578   temporal relationship, dechallenge and rechallenge where available, evaluation of alternative
1579   explanations and consistency across cases).

1580   Key uncertainties and limitations should be explicitly acknowledged, including small numbers of cases,
1581   incomplete documentation, reporting bias, confounding by underlying disease or concurrent medication
1582   and uncertainty in exposure and frequency estimates, together with their impact on interpretation of
1583   frequency and severity. Limitations of studies and other literature may also be summarised.

1584   Overall, the conclusion should set out a reasoned, evidence‑based assessment of the likelihood of a
1585   causal association, providing a transparent and proportionate basis for choosing the correct outcome of
1586   the signal assessment.

1587   2.5. Outcomes

1588   The outcome of the signal assessment and the justification thereof, shall be recorded internally and the
1589   rationale shall be kept ready for inspection17. The justification should explain the reasoning behind the
1590   outcome, not simply confirm that data were reviewed.

1591   All validated and assessed signals, including refuted signals and signals under close monitoring, should
1592   be submitted to IRIS-VSM in accordance with the Best Practice Guide9.

1593   Where the regulatory outcome of the signal assessment differs from the MAH’s initial proposal, it is
1594   expected that the MAH takes due account of the position (e.g. when conducting follow-up activities), in
1595   line with its pharmacovigilance obligations under Regulation (EU) 2019/6.

1596   A signal assessment should culminate in one of the following outcomes: the signal is refuted, the signal
1597   is placed under close monitoring, or the signal is determined to require risk minimisation measures.

1598   2.5.1. Signal refuted

1599   A refuted signal is a validated signal for which, following further assessment, a causal association is not
1600   supported by the available evidence at the time of assessment. The subject of the signal should return
1601   to routine pharmacovigilance activities. However, a refuted signal may be considered again as a
1602   potential signal, and it may be re-detected and re-submitted if new relevant information becomes
1603   available (see section 2.2.2).


       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                             Page 66/79

第 67 页

1604   Refuted signals should not be confused with non-validated signals (see section 2.3.2.2). Non-validated
1605   signals have not undergone full signal assessment and therefore the question of causality has not been
1606   considered.

1607   Where signal assessment has been completed and the available evidence was not sufficient to support
1608   a causal association, the rationale should be clearly documented. See also section 2.4 regarding factors
1609   to consider.

1610   2.5.2. Signal under close monitoring

1611   Where signal assessment indicates a potential causal association between the VMP and the adverse
1612   event, but the available evidence is currently insufficient to confirm or refute this association, the
1613   signal is not closed and the VMP is placed under close monitoring. At the time of assessment, the
1614   signal does not justify immediate risk minimisation measures.

1615   Signals under close monitoring require increased pharmacovigilance activities, which may include
1616   increased monitoring frequency, a focus on specific searches, targeted follow-up of incoming adverse
1617   event reports, initiation of a PMSS or survey etc. The scope and nature of monitoring should be
1618   determined by the data required to conclude the signal assessment, including focused review of
1619   relevant incoming information and consideration of cumulative as well as period-specific data. The
1620   signal should be re-assessed as additional evidence becomes available.

1621   MAHs are required to submit follow-up assessments of their findings to IRIS-VSM at the latest at the
1622   next annual statement submission date. Shorter reporting intervals may be set by the MAH or in
1623   certain circumstances by regulators. If shorter reporting intervals are set by the MAH, they are
1624   encouraged to notify the relevant regulators by including this information in the signal assessment
1625   report. The signal assessment report should clearly state the additional data which has been
1626   considered since the last submission as well as a reasoning for the proposed outcome.

1627   Signals under close monitoring would normally be expected to progress to a conclusion (signal refuted
1628   or signal requiring risk minimisation measures) within two years. Where close monitoring needs to
1629   extend beyond this period, the continued need for close monitoring should be justified, taking into
1630   account whether the data required to conclude the signal assessment can reasonably be expected to
1631   become available. Cessation of close monitoring may be proposed by submitting a new signal (e.g.
1632   with the proposed outcome of ‘refuted’ or ‘amendment of the product information’), supported by a
1633   detailed justification. The justification provided within the signal submission will be assessed by
1634   regulators and the MAH will be informed of the recommended outcome (see also section 3.1.2.3).

1635   For signals related to outcomes with long latency or slow accumulation of evidence (e.g. neoplasia or
1636   rare adverse events in specific sub-populations), longer periods of close monitoring may be
1637   appropriate, provided that this is supported by a clear scientific rationale and an active monitoring
1638   strategy. If uncertainty remains despite close monitoring, further data generation (e.g. post-marketing
1639   surveillance studies) should be considered.

1640   2.5.2.1. Post marketing surveillance studies

1641   In accordance with Article 15(1) of Commission Implementing Regulation (EU) 2021/1281 post-
1642   marketing surveillance studies may be conducted by MAHs on their own initiative or shall be conducted
1643   by MAHs on request of a competent authority or the Agency in accordance with Article 76(3) and (4) of
1644   Regulation (EU) 2019/6.




       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                              Page 67/79

第 68 页

1645   2.5.3. Signal requiring risk minimisation measures

1646   A signal requiring risk minimisation measures is a validated signal for which signal assessment
1647   supports a likely causal association between the VMP and the adverse event. The signal is considered
1648   to warrant risk minimisation measures.

1649   Where a signal requires risk minimisation measures, appropriate measures should be identified and
1650   implemented in a timely manner. The choice of risk minimisation measures should be proportionate
1651   (see also section 2.6).

1652

        Outcome of assessment                      At the time of assessment            Next step

        Signal refuted                             Causality not supported              Routine pharmacovigilance
                                                                                        activities

        Signal under close monitoring              Potential causal association;        Additional activities (in addition
                                                   evidence inconclusive                to routine monitoring),

                                                                                        Periodic update with signal re-
                                                                                        assessment

        Signal requiring risk                      Causality supported                  Implementing risk minimisation
        minimisation measures                                                           measures, monitor
                                                                                        effectiveness,

                                                                                        Routine pharmacovigilance

1653

1654      Table 2: Summary of signal assessment outcomes and subsequent actions

1655   2.6. Risk minimisation measures

1656   Risk minimisation measures are interventions intended to reduce the occurrence, severity and / or
1657   impact of adverse events associated with veterinary medicines. Their aim is to support veterinary
1658   healthcare professionals and animal owners in addressing the risks associated with veterinary
1659   medicines.

1660   The key routine risk minimisation tools available for authorised veterinary medicines are the summary
1661   of product characteristics (SPC) and the package leaflet (PL). These documents include a description of
1662   the risk of use of the veterinary medicine and intended actions for risk minimisation (e.g.
1663   contraindications for use). Following signal assessment it may be concluded that risk minimisation
1664   measures are required to help manage a specific risk that has been identified.

1665   If it is concluded that a causal association with a new or changed risk is considered likely (see also
1666   sections 2.4 and 2.5) then the need for any of the risk minimisation measures described in this section
1667   and/or any other measures should be considered, including a variation to the terms of the marketing
1668   authorisation. It is recommended to follow up on the effect of risk minimisation measures on the
1669   identified risk. Additionally, MAHs may be requested to specifically evaluate the impact.

1670   2.6.1. Amendment of the product information

1671   Following signal assessment changes to the product information may be required by either the
1672   addition, amendment or removal of currently authorised text e.g. in the SPC:

1673       •    Section 3.2 e.g. removal or restriction of an indication.

       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                                      Page 68/79

第 69 页

1674       •    Section 3.3 e.g. a new contraindication.

1675       •    Section 3.5 e.g. a new special precaution for use in the target species, user safety or
1676            environmental risks.

1677       •    Section 3.6 e.g. a new adverse event or change of frequency.

1678       •    Section 3.7 e.g. addition of a warning that the product cannot be used during pregnancy or
1679            lactation.

1680       •    Section 3.8 e.g. limitations on concurrent use with other medicinal products.

1681       •    Section 3.9 e.g. a change to instructions for use.

1682       •    Section 3.10 e.g. addition of clinical signs of overdose.

1683       •    Section 3.11 e.g. special restrictions for use.

1684       •    Section 10 e.g. a change to the prescription classification.

1685   The Regulatory outcome of the signal in IRIS will be published as ‘Amendment of the product
1686   information’ and, in accordance with Article 77(10) of Regulation (EU) 2019/6, the applicant should
1687   submit either a G.I.19 or G.I.4 variation requiring assessment. This variation will be assessed by the
1688   relevant authorities as per the established variation procedures.

1689   When submitting the variation, the MAH should refer to all relevant guidance on variations requiring
1690   assessment. Depending on the update, it may be necessary for MAHs to publish communication to end
1691   users informing of the change to the product information. EMA/the NCAs may also publish
1692   communication regarding changes to product information if considered necessary.

1693   As stated in section 2.3.1.2 if the product information update is related to harmonisation with the
1694   reference product, then this is not considered part of the signal management process and should be
1695   addressed via the relevant variation procedure.

1696   2.6.2. Additional risk communication

1697   Following signal assessment, if there is a need for immediate or targeted risk communication, a Direct
1698   Animal Healthcare Professional Communication (DaHPC) can be circulated to veterinarians and other
1699   animal healthcare professionals to inform them of important new safety information about a veterinary
1700   medicine and any actions they should take. This could be to advise that:

1701       •    A new serious adverse event has been discovered which requires direct communication with
1702            animal healthcare professionals.

1703       •    Another important change has occurred e.g. a restriction of an indication, a new
1704            contraindication, suspension, withdrawal or revocation of a product for safety reasons.

1705       •    The product isn't being used as intended e.g. where post-marketing surveillance has
1706            highlighted a need for increased awareness regarding specific characteristics of the product.

1707   DaHPCs should contain specific advice, recommendations or information regarding a veterinary
1708   pharmacovigilance concern, in particular which may require certain action to be taken or changes in
1709   relation to the administration of a VMP.




       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                              Page 69/79

第 70 页

1710   For more detailed information on the preparation, content, approval and dissemination of DaHPCs
1711   please refer to the VGVP module on veterinary pharmacovigilance communication 19.

1712   Other communication initiatives could include short information videos on EMA/NCA/MAH websites,
1713   publication of articles raising awareness of an identified risk in veterinary journals or information on
1714   the correct use of a product to minimise risk for the animal or the user.


1715   2.6.3. Batch recall, suspension, withdrawal or revocation of the marketing
1716   authorisation

1717   On occasion, the risk identified during signal assessment may require the recall of particular batches of
1718   product(s). This recall can be to wholesale, veterinary or other end user level (e.g. farmers, companion
1719   animal owners, etc). On rare occasions, in accordance with Article 129 of Regulation (EU) 2019/6, the
1720   suspension of the sale of any of the product may be required for a certain period of time until the
1721   identified risk has been mitigated.

1722   On very rare occasions, if the newly identified or changed risk(s) is deemed to outweigh the benefit of
1723   the product then the marketing authorisation may be revoked, meaning the VMP is withdrawn from the
1724   market and cannot be marketed anymore without submission of a new marketing authorisation
1725   application 20.

1726   2.6.4. Other risk minimisation measures

1727   In addition to the risk minimisation measures listed above other less frequently used measures are
1728   also available if required.

1729   2.6.4.1. Educational material

1730   Another option for minimising an identified risk and assisting with measures for prevention could be to
1731   provide educational material.

1732   Examples may include:

1733       •    Printed leaflets for distribution in veterinary practices or other animal healthcare settings.

1734       •    In-person training for veterinarians/other animal healthcare professionals by representatives of
1735            the MAH.

1736       •    MAH/NCA social media content.

1737       •    Internal training of sales representatives/product managers or other relevant staff.

1738       •    Creation of a user manual or update of an existing user manual.

1739   See examples 87-89.




       19 https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-veterinary-good-

       pharmacovigilance-practices-vgvp-module-veterinary-pharmacovigilance-communication_en.pdf
       20 Article 130 of Regulation (EU) 2019/6


       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                                  Page 70/79

第 71 页

            Examples

            87: A signal of a medication error concerning product use leading to increased risk to users: An
                  educational video or pamphlet is made to support the correct use and administration of the
                  product to avoid accidents.

            88: A signal concerning user safety with a very toxic substance (e.g. products used for
                  chemotherapy): A video or pamphlet is made explaining the importance and showing the
                  correct use of personal protective equipment.

            89: A signal where adequate monitoring may prevent the AE: A pamphlet is created for the vet
                  and a ’monitoring’ schedule/diary for the owner to help them keep track of veterinary visits
                  and explain the importance of them.
1740




       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                            Page 71/79

第 72 页

1741   3. Reporting to the EU network
                             Signal management reportings                                 Other reportings

                             Annual                Signals              PhV alerts        Sales data &       Regulatory
                             statements                                                   dose factor        measures
                                                   (section 3.1.2)      (section 3.1.3)
                                                                                                             worldwide
                             (section 3.1.1)                                              (section 3.2.1)
                                                                                                             (section 3.2.2)

        Frequency and        Annually              Action               Within 3 days     Annually (end      Within 30 days
        timing                                     required:            of detection      of February)
                             (due date), or
                                                   within 30 days
                             higher
                                                   of assessment
                             frequency, if
                             applicable

                                                   no action: at
                                                   the latest by
                                                   due date

        Where                IRIS-VSM              IRIS-VSM             IRIS-VSM          UPD                IRIS-VSM

        Relevant links       IRIS portal           IRIS portal          IRIS portal       UPD portal         IRIS portal

                             Due date list         BPG                                    Dose factor
                                                                                          guidance
                                                   AR template



1742      Table 3: Reporting to the EU network

1743   3.1. Signal management reporting obligations

1744   MAHs are responsible 21 for continuously monitoring the benefit-risk balance of their VMPs, conducting
1745   the signal management process in compliance with the pharmacovigilance guidelines and recording
1746   their conclusions in the UPhV-database (IRIS-VSM).

1747   There are two main reporting responsibilities for MAHs; the annual conclusion on the benefit-risk
1748   balance (annual statement), which needs to be submitted at least annually for all VMPs with a valid
1749   marketing authorisation and the submission of all validated and assessed signals as applicable.

1750   Signal management submissions and annual statement submissions are also accessible by the public
1751   on the IRIS platform (public register) 22.

1752   3.1.1. Annual statements

1753   As laid down in the regulations, MAHs shall at least annually record a conclusion on the benefit-risk
1754   balance for each of their products in the UPhV-database and confirm that the signal management
1755   process has been conducted 23. This should be done irrespective of whether any signals were detected
1756   throughout the year. Furthermore, it applies to all VMPs with a valid marketing authorisation,
1757   regardless of the marketing status. Where MAHs are responsible for the same or a similar veterinary


       21 Article 77 of Regulation (EU) 2019/6 and Article 18 of CIR (EU) 2021/1281
       22 https://iris.ema.europa.eu/publicregistersignal/
       23 Article 81(2) of Regulation (EU) 2019/6 and Article 19 of CIR (EU) 2021/1281


       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                                        Page 72/79

第 73 页

1758   medicinal product 24, authorised in different Member States through different authorisation procedures,
1759   the signal management process may be performed at active substance level for all the products
1760   combined.

1761   At the time of submission of the annual statement, the MAH will have to confirm that all validated
1762   signals have been submitted following assessment accordingly in the UPhV-database (IRIS-VSM).

1763   All MAHs shall conduct at least one signal detection analysis per year for each of their active
1764   substances or products in the UPhV-database7. This signal detection analysis should be performed
1765   within 2 months before the annual due date (see section 2.1).

1766   3.1.1.1. Marketing authorisation holder’s responsibilities

1767   The responsibility for the MAH to submit an annual statement in accordance with Regulation (EU)
1768   2019/6 is independent of the marketing status. Even if an authorised VMP is not marketed after
1769   authorisation, the annual statement should be submitted annually.

1770   In order to limit administrative burden, it is permitted to group same or similar products 25 from the
1771   same MAH and submit a grouped annual statement. However, it is not permitted to group products
1772   that are not the same or similar e.g. pharmaceuticals and immunologicals.

1773   If the marketing authorisation of a VMP is suspended this does not affect the requirement to submit an
1774   annual statement, since this situation corresponds to a temporary marketing cessation which could be
1775   lifted. The usual requirements in terms of annual statement submission apply. In this case the option
1776   in the annual statement ‘The marketing authorisation is currently suspended for reasons related to
1777   safety’ should be chosen.

1778   In all other cases, the MAH is asked to confirm that the benefit-risk balance remains favourable. This
1779   option should also be chosen in case a variation is ongoing concerning the safety of the VMP.

1780   For VMPs for which the marketing authorisation has been withdrawn, revoked or surrendered, there is
1781   no need to submit annual statements after cessation of validity of the marketing authorisation.

1782   3.1.1.2. Timelines for annual statement submissions (recommended due dates)

1783   Annual statements should be submitted in accordance with the list of recommended due dates 26 for
1784   VMPs including homeopathic medicinal products.

1785   The due dates are allocated to ATCvet codes and spread throughout the year with the aim to even out
1786   the submission of annual statements.

1787   MAHs with VMPs with an ATCvet code that is not already included in the list of due dates are advised to
1788   send a proposal for a due date to EMA via the ‘Send a question to EMA online form’ 27. The proposed
1789   new due date may take into account similar ATCvet codes with their assigned due dates. The MAH will
1790   be informed about the allocated date in due course.




       24 Article 17(2) of Commission Implementing Regulation (EU) 2021/1281
       25 https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl24-guideline-pharmacovigilance-veterinary-

       medicinal-products-management-adverse-event-reports-aers_en.pdf
       26 https://www.ema.europa.eu/en/documents/other/recommended-due-dates-submitting-annual-statements-centrally-non-

       centrally-authorised-products-caps-non-caps-homeopathic-medicinal-products_en.xlsx
       27 https://www.ema.europa.eu/en/about-us/contacts-european-medicines-agency/send-question-european-medicines-

       agency

       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                                       Page 73/79

第 74 页

1791   At least once a year the list of recommended due dates will be updated with the new ATCvet codes as
1792   applicable and published on the EMA website 28.

1793   MAHs are reminded that the conclusion on the benefit-risk balance shall be recorded at least
1794   annually23. ‘Annually’ should be understood as within a 12 months’ time period and it is strongly
1795   recommended to submit them according to the due dates in order to facilitate the predictability of the
1796   annual statement submissions and to even out the workload of all involved stakeholders.

1797   It should be emphasised that the annual submission of all results and outcomes of the signal
1798   management process, including a conclusion on the benefit-risk balance, is the default option.
1799   However, some VMPs can have a higher frequency as a requirement of the marketing authorisation23
1800   or recommended by competent authorities/the Agency. In such cases, the annual statement should be
1801   submitted in accordance with the requested frequency.

1802   3.1.1.3. EU network/NCAs’ responsibilities

1803   Although the main responsibility for the assessment of the benefit-risk balance lies with the MAH, the
1804   regulators may perform an analysis following a risk-based approach to determine whether the MAH has
1805   detected and submitted all relevant signals in accordance with section 3.1.2.

1806   Any identified discrepancies and recommended risk minimisation measures (see section 2.6) will be
1807   communicated to the MAH.

1808   Furthermore, in some Member States, additional national legal requirements may exist for national
1809   competent authorities to perform safety surveillance/pharmacovigilance especially for nationally
1810   authorised VMPs, which may translate into specific requests to MAHs.

1811   3.1.2. Signal submissions

1812   3.1.2.1. Marketing authorisation holder’s responsibilities

1813   It is the responsibility of the MAH to continuously monitor the benefit-risk balance of their VMPs.

1814   The MAH should notify any change to the benefit-risk balance or a new risk to the competent
1815   authorities or to the Agency as applicable without delay and no later than within 30 days and take the
1816   necessary action 29.

1817   The notification of a signal should be done through the IRIS-VSM platform 30 for all validated signals
1818   once the assessment has been finalised, regardless of the MAH’s conclusions. Detailed guidance on the
1819   functionality is available on the IRIS platform page 31. In addition, the Veterinary Union
1820   Pharmacovigilance Database - Best Practice GuideError! Bookmark not defined. provides further practical
1821   guidance for signal submissions.

1822   The MAHs are advised to send separate signals for VeDDRA terms that are not medically linked, as well
1823   as for each target species. Same or similar products from the same MAH as well as medically linked
1824   VeDDRA terms (even if they are included in different SOCs) can be grouped in one signal submission.
1825   However, separate signals should be submitted for different proposed outcomes.




       28 https://www.ema.europa.eu/en/veterinary-regulatory-overview/post-authorisation-veterinary-

       medicines/pharmacovigilance-veterinary-medicines/signal-management-veterinary-medicines
       29 Articles 81(2) and 77(10) of Regulation (EU) 2019/6
       30 https://iris.ema.europa.eu/
       31 https://iris.ema.europa.eu/homeguidance/


       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                              Page 74/79

第 75 页

1826   The signal submission should be accompanied by an assessment report 32 outlining the
1827   pharmacovigilance data and their evaluation, as well as the conclusions of the MAH. In certain cases,
1828   several related signals are assessed in one assessment report. In such a case the same assessment
1829   report can be uploaded for several signal submissions.

1830   Once a signal has been submitted via the IRIS-VSM platform it can, in general, not be amended.
1831   However, in case of a mistake, the MAH can request a correction via the EMA IT service desk 33.

1832   Changes to a submitted signal should not be done after the regulatory assessment has been concluded
1833   and the outcome has been published in IRIS, unless there is a specific request for a correction by the
1834   responsible competent authority.

1835   For further information on the possible conclusions of the signal evaluation, please see section 2.5.

1836   In general, when the outcome of a signal leads to an amendment of the product information, it is
1837   expected that a signal with the MAHs conclusion ‘Amendment of the product information’ is submitted
1838   in IRIS.

1839   However, in case the amendment of the product information has been requested by the responsible
1840   competent authority/ the CVMP following assessment of an already existing signal, then a variation can
1841   be directly submitted.

1842   For VMPs for which the marketing authorisation has been withdrawn, revoked or surrendered it is
1843   strongly recommended that the MAH continues to perform pharmacovigilance activities, taking into
1844   consideration the recommendations in the VGVP module on collection and recording of suspected
1845   adverse events for veterinary medicinal products8.

1846   3.1.2.2. Timelines for signal management submissions

1847   For validated signals for which the MAH identified a change to the benefit-risk balance or a new risk
1848   (e.g. the MAH proposes regulatory or other actions in accordance with section 2.5.3), the legal
1849   notification time 34 is no later than 30 days after finalisation of the signal assessment. As the benefit-
1850   risk balance of a product needs to be monitored by the MAH continuously, the signal management
1851   submission can therefore occur at any time throughout the year.

1852   When submitting a signal, it is recommended that the data lock point (DLP) in the assessment report is
1853   not older than 3 months.

1854   For assessed signals for which the MAH proposes a refutation or close monitoring, the corresponding
1855   signals can be submitted by the time of the submission of the annual statement (see also section
1856   3.1.1).

1857   Pharmacovigilance alerts (see also sections 2.2.1.1 and 3.1.3) should be notified as soon as possible
1858   and no later than 3 working days following their identification by the MAH.

1859   3.1.2.3. EU network/NCAs’ responsibilities

1860   The competent authorities and the Agency evaluate the results and outcomes of the signal
1861   management process, consider options for risk management and recommend appropriate measures
1862   referred to in Articles 129, 130 and 134 concerning marketing authorisations 35.


       32 https://www.ema.europa.eu/en/documents/template-form/veterinary-signal-assessment-report-marketing-

       authorisation-holders_en.docx
       33 https://support.ema.europa.eu/esc
       34 Article 81(2) of Regulation (EU) 2019/6
       35 Article 79 of Regulation (EU) 2019/6


       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                                    Page 75/79

第 76 页

1863   All submitted signals by the MAH will be evaluated by an assigned responsible competent authority and
1864   the proposed regulatory outcome agreed with other competent authorities where the affected VMPs are
1865   authorised or adopted by the CVMP as applicable.

1866   In the situation where the regulatory outcome is in agreement with the proposed outcome by the MAH,
1867   the outcome will be published on the IRIS platform. In case of differences to the MAH’s outcome, these
1868   will be outlined in an assessment report and communicated to the MAH before publication of the
1869   regulatory outcome on the IRIS platform.

1870   3.1.3. Pharmacovigilance Alerts

1871   Pharmacovigilance (PhV) alerts (see section 2.2.1.1.) should be reported to the relevant competent
1872   authority(ies) of the Member State(s) where the VMP is authorised and the Agency without delay and
1873   no later than 3 working days after its identification.

1874   The notification of a PhV alert should be done through the IRIS-VSM platform30 specifying the type of
1875   signal as ‘Pharmacovigilance alert’.

1876   When notifying a PhV alert, the MAH should describe the safety issue, the source(s) of information,
1877   actions taken or any planned actions with timelines and should provide any relevant documentation
1878   available at the time of initial notification. Any further information relevant to the issue should be
1879   provided to the Agency and relevant national competent authorities as soon as it becomes available.

1880   Upon being notified of a PhV alert, the national competent authorities or the Agency as appropriate will
1881   promptly assess the urgency and potential impact of the issue and agree on appropriate next steps and
1882   the potential regulatory procedure to address the matter raised. This may involve consultation with the
1883   incident review network, if warranted (see incident management plan for medicines for veterinary
1884   use 36). The MAH should collaborate with the Agency and national competent authorities in the
1885   assessment of pharmacovigilance alerts.

1886   3.2. Other reporting obligations

1887   3.2.1. Reporting of sales data and calculation of dose factor

1888   The Union Product Database shall contain the annual volume of sales and information on the
1889   availability for each VMP 37. It is the responsibility of the MAH to record in the UPD the annual volume
1890   of sales for each of its VMPs 38.

1891   The sales data should be recorded in the UPD by the end of February of each calendar year 39, 40.

1892   In addition to sales data, the MAH is also obliged to calculate and submit a dose factor; please see
1893   guideline on the calculation of dose factor 41. Documentation should be maintained within the MAH’s
1894   pharmacovigilance system.




       36
          https://www.ema.europa.eu/en/veterinary-regulatory-overview/post-authorisation-veterinary-
       medicines/pharmacovigilance-veterinary-medicines/incident-management-plan-veterinary-medicines
       37 Article 55(2d) of Regulation (EU) 2019/6
       38 Article 58(12) of Regulation (EU) 2019/6
       39 UPD - Questions and Answers
       40 https://www.ema.europa.eu/en/documents/other/eu-implementation-guide-ig-veterinary-medicines-product-data-union-

       product-database-chapter-7-submission-other-post-authorisation-data_en.pdf
       41 https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-calculation-dose-factor-be-submitted-union-

       product-database-upd_en.pdf

       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                                     Page 76/79

第 77 页

1895   As described in Article 75(3) from Regulation (EU) 2019/6, the annual incidence data from suspected
1896   adverse events for each VMP by animal species and type of suspected adverse event should be made
1897   available for access to the general public in the UPhV-database (ADR website).


1898   3.2.2. Notification on regulatory measures from non-EU regulatory
1899   agencies/Information from other regulatory authorities worldwide

1900   Article 78(1)(k) of Regulation (EU) 2019/6 tasks the QPPV to communicate any regulatory measure
1901   taken by a competent authority in a third country and that is related to pharmacovigilance data to the
1902   competent authorities and to the Agency within 21 days of receipt of such information.

1903   These notifications should be submitted via the IRIS-VSM platform30 as signal type ‘Submission of
1904   regulatory measure acc. to Art.78 1(k) of the Regulation 2019/6’.

1905




       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                         Page 77/79

第 78 页

1906   4. Targeted signal management by the competent authorities
1907   and the Agency
1908   As described in Article 81(3) from Regulation (EU) 2019/6, the competent authorities and the Agency
1909   have the option to perform a targeted signal management process for a given VMP or group of VMPs.

1910   Regulators can start a Targeted Signal Management (TSM) procedure at any time throughout the year.
1911   The start of a TSM will be published on the EMA website 42 and concerned MAHs will be informed
1912   accordingly. MAHs should collaborate with the Agency and national competent authorities in any TSM
1913   initiated by the competent authorities and provide any requested information in a timely manner.

1914   More detailed guidance on the targeted signal management procedure will be published separately.


1915   5. Documentation requirements related to the Signal
1916   Management Process
1917   Signal management is considered a critical process and shall therefore be well documented. MAHs shall
1918   ensure that their processes, procedures and policies to fulfil their obligations related to the signal
1919   management process and its related tasks are functioning properly and efficiently and are
1920   appropriately documented as outlined in EU Regulation 2019/6 and CIR (EU) 2021/1281. A quality
1921   management system shall be applied throughout. Please also refer to VGVP module:
1922   Pharmacovigilance systems, their quality management systems and pharmacovigilance system master
1923   files 43.

1924   It is important that the roles of all staff members involved are clearly defined and the individuals
1925   tasked with these responsibilities have the necessary qualifications and expertise to do so.
1926   Documentation regarding qualifications and training of relevant staff members should be kept up to
1927   date and available. It is expected that any IT-System used for and in conjunction with the signal
1928   management process and adverse event analysis is validated, approved and deemed as 'fit for
1929   purpose' by the QPPV and IT personnel. The relevant documentation for this is to be kept available for
1930   pharmacovigilance inspections.

1931   When the MAH opts to use its own database for signal detection and analysis, detailed description of
1932   the data collection process, the data-tables and statistical measures available and routinely used shall
1933   be made available on request or at the time of pharmacovigilance inspections.

1934   Upon inspection it is required that the entire process is not only described theoretically but also backed
1935   up with the appropriate documentation of its application. This includes the rationale for the method
1936   and periodicity of signal management activities and the individual steps applied throughout. Through a
1937   tracking system, all organisations should keep an audit trail of all signal management activities,
1938   allowing traceability (i.e. recording of dates and confirmation of timeliness) and process control of the
1939   details of all steps of signal management, including analyses, decisions and rationale.

1940   In summary, as a minimum, MAHs are expected to have procedures describing in details the overall
1941   signal management process and, for each step, how signal management is effectively carried out, i.e.
1942   for signal detection, signal prioritisation, signal validation, signal assessment, handling of potential
1943   pharmacovigilance alerts, submission of outcomes (signals and outcome statement to the EU network

       42 https://www.ema.europa.eu/en/veterinary-regulatory-overview/post-authorisation-veterinary-

       medicines/pharmacovigilance-veterinary-medicines/signal-management-veterinary-medicines#targeted-signal-
       management-by-regulators-14572
       43 https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-veterinary-good-

       pharmacovigilance-practices-vgvp-module-pharmacovigilance-systems-their-quality-management-systems-and-
       pharmacovigilance-system-master-files_en.pdf

       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                                      Page 78/79

第 79 页

1944   and relevant NCA). The level of details expected in procedures should be sufficient to allow,
1945   theoretically, any new employee to perform the corresponding tasks, should they have the relevant
1946   expertise.

1947       •    Overall signal management process.

1948       •    Procedure for signal detection (both in the UPhV-Database and MAH databases, if applicable).

1949       •    Overall policy and procedure for the remaining individual steps of the signal management
1950            process, namely:

1951                 o    Signal prioritisation,

1952                 o    Signal validation,

1953                 o    Signal assessment,

1954                 o    Handling of potential Pharmacovigilance Alerts,

1955                 o    Submission of the outcomes of the signal management process (signals and annual
1956                      statements) to the EU Network and relevant NCAs.

1957   Documentation of the application of above-mentioned procedures including their outcomes should be
1958   kept available. This includes, but is not limited to;

1959       •    Established risk-based monitoring criteria for each product or group of products (how often and
1960            by which methods is monitoring performed for each product/product group and why?).

1961       •    Compliance with established monitoring criteria.

1962       •    Signal validations performed, their outcome and rationale.

1963       •    Signal assessments performed.

1964       •    Reporting of the outcome of the signal management process (signals and annual statements)
1965            to the EU Network and relevant NCAs.

1966   Documents and pharmacovigilance data relating to individual authorised veterinary medicinal products
1967   shall be retained as long as the product is authorised and for 5 years after the marketing authorisation
1968   ceases to be valid. 44




       44 CIR (EU) 2021/1281 Article 5(3)


       Guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal
       Management
       EMA/522332/2021 Rev.1                                                                           Page 79/79

来源:EMA 官方医药监管信息 · ema.europa.eu